[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2596
1. Tamura K, Kikui K, Watanabe M: Caring for the spiritual pain of patients with advanced cancer: A phenomenological approach to the lived experience. Palliat Support Care; 2006 Jun;4(2):189-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caring for the spiritual pain of patients with advanced cancer: A phenomenological approach to the lived experience.
  • OBJECTIVE: The aim of this research was to reveal, from the perspective of the "lived experience" shared by cancer patients and their nurses, how patients facing death create lived experience in the context of palliative care.
  • METHODS: The participants in this study were cancer patients who were given opportunities to discuss events and concerns in their daily lives, with the interactions guided by the researchers.
  • SIGNIFICANCE OF RESEARCH: This research elucidates the spiritual pain experienced by cancer patients and discusses opportunities for nurses to address the spiritual care of these patients.


2. Ellegård LH, Ahlén M, Körner U, Lundholm KG, Plank LD, Bosaeus IG: Bioelectric impedance spectroscopy underestimates fat-free mass compared to dual energy X-ray absorptiometry in incurable cancer patients. Eur J Clin Nutr; 2009 Jun;63(6):794-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioelectric impedance spectroscopy underestimates fat-free mass compared to dual energy X-ray absorptiometry in incurable cancer patients.
  • BACKGROUND/OBJECTIVES: Weight loss is frequently seen in advanced cancer.
  • We examined in a prospective, comparative study if BIS could accurately estimate fat-free mass (FFM) in cancer patients compared to dual-energy X-ray absorptiometry (DXA).
  • SUBJECTS/METHODS: The study was based on 132 consecutive incurable cancer patients with solid tumours in a University hospital outpatient clinic.
  • CONCLUSIONS: BIS by standard equations grossly underestimates FFM compared to DXA in cancer patients.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478025.001).
  • [ISSN] 1476-5640
  • [Journal-full-title] European journal of clinical nutrition
  • [ISO-abbreviation] Eur J Clin Nutr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


3. Eucker J, Kühnl A, Possinger K: [Systemic therapy of male breast cancer]. Zentralbl Chir; 2007 Oct;132(5):396-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic therapy of male breast cancer].
  • Due to its low incidence there is only few information on optimal systemic therapy of male breast cancer.
  • There are no prospective randomized trials, neither for early breast cancer nor for advanced stages.
  • In terms of epidemiology, cellular receptors or genetics there exist some significant differences between male and female breast cancer.
  • Therefore, the possibility to extrapolate treatment recommendation for male patients from female breast cancer-trials is limited.
  • Cytostatic therapy seems to be as effective as in female breast cancer patients.
  • Nevertheless, convincing prospective trials for the management of early and advanced male breast cancer need to be performed.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907081.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 094ZI81Y45 / Tamoxifen; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


Advertisement
4. Miyashita M, Hirai K, Morita T, Sanjo M, Uchitomi Y: Barriers to referral to inpatient palliative care units in Japan: a qualitative survey with content analysis. Support Care Cancer; 2008 Mar;16(3):217-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We investigated the barriers to referral to inpatient palliative care units (PCUs) through a qualitative study across various sources of information, including terminal cancer patients, their families, physicians, and nurses.
  • MATERIALS AND METHODS: There were 63 participants, including 13 advanced cancer patients, 10 family members, 20 physicians, and 20 nurses in palliative care and acute care cancer settings from five regional cancer institutes in Japan.
  • The leading barriers were (1) a negative image of PCUs by patients and families (n = 39), (2) delay of termination of anti-cancer treatment by physicians in the general wards (n = 24), (3) unwillingness to end anti-cancer treatment and denial of the fatal nature of the disease by patients and families (n = 22), (4) patient's wish to receive care from familiar physicians and nurses (n = 20), and (5) insufficient knowledge of PCUs by medical staff in general wards (n = 17).
  • In addition, early introduction of palliative care options to patients and communication skills training regarding breaking bad news are relevant issues for a smooth transition from anti-cancer treatment to palliative care.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2637-44 [15728219.001]
  • [Cites] J Palliat Med. 2007 Apr;10(2):390-9 [17472511.001]
  • [Cites] J Palliat Med. 2004 Jun;7(3):411-8 [15265350.001]
  • [Cites] Palliat Med. 1997 Sep;11(5):351-7 [9472591.001]
  • [Cites] J Pain Symptom Manage. 2006 Apr;31(4):306-16 [16632078.001]
  • [Cites] J Pain Symptom Manage. 2005 Nov;30(5):400-7 [16310614.001]
  • [Cites] Palliat Med. 2005 Jun;19(4):319-27 [15984504.001]
  • [Cites] Omega (Westport). 1997;35(2):193-217 [11660418.001]
  • [Cites] Palliat Med. 2003 Jul;17(5):445-53 [12882263.001]
  • [Cites] Death Stud. 1999 Apr-May;23(3):225-38 [10848152.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1551-7 [15367417.001]
  • [Cites] WMJ. 1999 May-Jun;98(3):49-53 [10414220.001]
  • [Cites] J Palliat Med. 2002 Feb;5(1):85-92 [11839230.001]
  • [Cites] Palliat Med. 2004 Sep;18(6):525-42 [15453624.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2049-56 [11283138.001]
  • [Cites] Chest. 2000 Oct;118(4):1172-82 [11035693.001]
  • [Cites] J Palliat Med. 2001 Winter;4(4):491-7 [11798481.001]
  • [Cites] Palliat Med. 1996 Jul;10(3):251-7 [8817597.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3490-6 [16849766.001]
  • [Cites] Ann Intern Med. 1997 Aug 1;127(3):225-30 [9245229.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):503-13 [11786580.001]
  • [Cites] Palliat Med. 2004 Apr;18(3):202-16 [15198133.001]
  • [Cites] J Palliat Med. 2002 Feb;5(1):73-84 [11839229.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2012-9 [15774792.001]
  • [Cites] Palliat Med. 2002 May;16(3):179-84 [12046993.001]
  • [Cites] Am J Hosp Palliat Care. 2005 Mar-Apr;22(2):119-24 [15853089.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2189-96 [11956281.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1539-47 [17660496.001]
  • [Cites] Am J Hosp Palliat Care. 2004 May-Jun;21(3):196-202 [15188919.001]
  • (PMID = 17318594.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


5. Solit DB, Rosen N: Hsp90: a novel target for cancer therapy. Curr Top Med Chem; 2006;6(11):1205-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hsp90: a novel target for cancer therapy.
  • Experiments with these drugs have shown that Hsp90 is required for maintaining the malignant phenotype of cancer cells.
  • The basis for the therapeutic index (selective toxicity to cancer cells) of Hsp90 inhibitors is complex and may have to do with induction of degradation of mutant oncoproteins and other proteins necessary for their proliferation and survival as well as to an enhanced requirement of these cells for Hsp90 stress-survival functions.
  • Based on these data, 17-AAG, an ansamycin antibiotic inhibitor of Hsp90, is being tested extensively in clinical trials in patients with advanced cancer.
  • These trials demonstrate that the biologic function of Hsp90 can be inhibited in patients and antitumor activity has been noted in patients with breast cancer, multiple myeloma and other cancers.
  • This article will review the preclinical data which supports the testing of Hsp90 inhibitors as cancer drugs and update the reader on the current status of the ongoing clinical trials of Hsp90 inhibitors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842157.001).
  • [ISSN] 1568-0266
  • [Journal-full-title] Current topics in medicinal chemistry
  • [ISO-abbreviation] Curr Top Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HSP90 Heat-Shock Proteins
  • [Number-of-references] 103
  •  go-up   go-down


6. Renz M, Schütt Mao M, Cerny T: Spirituality, psychotherapy and music in palliative cancer care: research projects in psycho-oncology at an oncology center in Switzerland. Support Care Cancer; 2005 Dec;13(12):961-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spirituality, psychotherapy and music in palliative cancer care: research projects in psycho-oncology at an oncology center in Switzerland.
  • Two research projects investigated the feasibility of psychotherapeutic and music therapeutic assistance offered to advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Palliat Care. 2001 Autumn;17(3):167-72 [11816757.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):11-20 [12597461.001]
  • [Cites] Oncologist. 2001;6(3):286-97 [11423676.001]
  • [Cites] Med J Aust. 2003 Sep 15;179(6 Suppl):S11-3 [12964927.001]
  • [Cites] Psychosomatics. 2002 May-Jun;43(3):213-20 [12075036.001]
  • [Cites] Oncol Nurs Forum. 1985 Sep-Oct;12(5):47-52 [3898031.001]
  • [Cites] Psychooncology. 1999 Sep-Oct;8(5):395-407 [10559799.001]
  • [Cites] Support Care Cancer. 2002 May;10(4):272-80 [12029426.001]
  • [Cites] BMJ. 1996 Jul 6;313(7048):29-33 [8664768.001]
  • [Cites] BMJ. 2002 Dec 21;325(7378):1434-5 [12493652.001]
  • [Cites] J Nurs Res. 2002 Dec;10(4):237-45 [12522736.001]
  • [Cites] J Palliat Care. 2001 Autumn;17(3):142-6 [11816753.001]
  • [Cites] Proc (Bayl Univ Med Cent). 2001 Oct;14(4):352-7 [16369646.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1091-6 [9834821.001]
  • [Cites] Cancer Pract. 2002 May-Jun;10 Suppl 1:S58-65 [12027971.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1603-7 [12747880.001]
  • (PMID = 16080014.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


7. Liu CS, Nagarsheth NP, Nezhat FR: Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer? J Minim Invasive Gynecol; 2009 May-Jun;16(3):250-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?
  • A MEDLINE search was conducted using the keywords "laparoscopy ovarian cancer," "laparoscopy and borderline ovarian tumors," "advanced stage ovarian cancer," "laparoscopic cytoreduction ovarian cancer," "laparoscopy intraperitoneal catheter," "port-site metastases," and "carbon dioxide pneumoperitoneum."
  • The publications were further limited to English-language articles, those addressing adnexal mass management, early stage ovarian cancer, and advanced stage ovarian cancer treatments.
  • The articles were divided into 4 broad categories: adnexal masses, low malignant potential tumors, early stage ovarian cancer, and advanced ovarian cancer.
  • The current literature defining the role of laparoscopy in the diagnosis and treatment of ovarian cancer is limited to case reports, case series, and cohort studies.
  • However, these limited studies suggest equal efficacy of laparoscopy compared with laparotomy in both early and advanced stage ovarian cancer.
  • [MeSH-minor] Female. Humans. Neoplasm Seeding. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Minim Invasive Gynecol. 2009 May-Jun;16(3):245-6 [19423055.001]
  • (PMID = 19321390.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 111
  •  go-up   go-down


8. Perdue C: Managing constipation in advanced cancer care. Nurs Times; 2005 May 24-30;101(21):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing constipation in advanced cancer care.
  • Constipation is a common and debilitating symptom in patients with advanced cancer.

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940972.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


9. Berretta M, Martellotta F, Simonelli C, Di Benedetto F, De Ruvo N, Drigo A, Bearz A, Spina M, Zanet E, Berretta S, Tirelli U: Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report. J Chemother; 2007 Jun;19(3):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
  • Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer.
  • In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer.
  • At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
  • This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cetuximab. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Humans. Leucovorin / administration & dosage. Leucovorin / therapeutic use. Middle Aged. Neoplasm Metastasis


10. Mystakidou K, Tsilika E, Parpa E, Katsouda E, Sakkas P, Soldatos C: Life before death: identifying preparatory grief through the development of a new measurement in advanced cancer patients (PGAC). Support Care Cancer; 2005 Oct;13(10):834-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life before death: identifying preparatory grief through the development of a new measurement in advanced cancer patients (PGAC).
  • GOALS OF WORK: This paper describes the development of a self-rating scale to measure preparatory grief in advanced cancer patients.
  • PATIENTS AND METHODS: The Preparatory Grief in Advanced Cancer patients (PGAC) instrument incorporates seven multi-items scales.
  • CONCLUSIONS: The PGAC is a reliable and valid measure for the assessment of anticipatory grief in patients with advanced stage cancer.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 1977 Jun;134(6):696-8 [869041.001]
  • [Cites] Cancer Nurs. 1995 Feb;18(1):35-46 [7866975.001]
  • [Cites] Ann Intern Med. 2000 Feb 1;132(3):209-18 [10651602.001]
  • [Cites] Am J Geriatr Psychiatry. 2003 Jul-Aug;11(4):393-405 [12837668.001]
  • [Cites] Postgrad Med. 1997 Mar;101(3):263-70 [9074563.001]
  • [Cites] Br J Med Psychol. 1986 Dec;59 ( Pt 4):305-10 [3801338.001]
  • [Cites] Psychooncology. 1999 Sep-Oct;8(5):439-50 [10559803.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] J Palliat Care. 1990 Autumn;6(3):7-11 [1700099.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Am Fam Physician. 2002 Mar 1;65(5):883-90 [11898960.001]
  • [Cites] Hosp J. 1986 Winter;2(4):21-36 [3647919.001]
  • [Cites] BMJ. 1998 Mar 14;316(7134):856-9 [9549464.001]
  • [Cites] Ann Intern Med. 2001 Feb 6;134(3):208-15 [11177334.001]
  • [Cites] Cancer Pract. 1998 Nov-Dec;6(6):333-8 [9824424.001]
  • [Cites] J Pastoral Care. 1991 Fall;45(3):254-67 [10114080.001]
  • [Cites] Psychother Psychosom. 1995;63(3-4):181-4 [7624464.001]
  • [Cites] Am J Nurs. 2003 Sep;103(9):42-6, 48-52; quiz 53 [14501473.001]
  • (PMID = 15864662.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Germany
  •  go-up   go-down


11. Kümmerlin IP, ten Kate FJ, Wijkstra H, de la Rosette JJ, Laguna MP: Changes in the stage and surgical management of renal tumours during 1995-2005: an analysis of the Dutch national histopathology registry. BJU Int; 2008 Sep;102(8):946-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean (sd) tumour size of malignant tumours decreased from 7.3 (3.6) to 6.9 (3.7) cm (P = 0.301).
  • There was an increase of grade 1 tumours; the incidence of T1 tumours increased from 36.6% to 44.2%, and advanced tumours decreased from 46.4% to 33.7%, respectively.
  • [MeSH-minor] Epidemiologic Methods. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Nephrons / pathology. Nephrons / surgery. Netherlands / epidemiology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564136.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Al Diab AI: Cancer-related venous thromboembolism: insight into underestimated risk factors. Hematol Oncol Stem Cell Ther; 2010;3(4):191-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-related venous thromboembolism: insight into underestimated risk factors.
  • BACKGROUND: Risk factors for cancer-associated VTE include certain cancer types (e.g. pancreatic adenocarcinoma), chemotherapy, and the use of erythropoiesis-stimulating agents, central venous catheters, and surgery.
  • We studied the risk factors for cancer-associated VTE in our institution.
  • CONCLUSION: VTE imposes a great risk to life in cancer patients.
  • Risk factors include age more than 40 years, advanced cancer stage, chemotherapy, use of EPO for anemia and underuse of DVT prophylaxis.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Anemia / drug therapy. Anticoagulants / therapeutic use. Catheterization, Central Venous. Erythropoietin / therapeutic use. Female. Hemoglobins / analysis. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Warfarin / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150239.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Hemoglobins; 0 / Heparin, Low-Molecular-Weight; 11096-26-7 / Erythropoietin; 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


13. Glare P, Walsh D, Sheehan D: The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care; 2006 Jun-Jul;23(3):229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain.
  • Little information is available about the incidence, prevalence, or severity of morphine side effects during repeated individualized dosing for chronic cancer pain, although it has been widely used in this way for more than 30 years.
  • The authors' aim was to describe the prevalence of symptoms possibly attributable to morphine side effects in a convenience sample of patients with pain due to advanced cancer.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060284.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


14. Brown P, Clark MM, Atherton P, Huschka M, Sloan JA, Gamble G, Girardi J, Frost MH, Piderman K, Rummans TA: Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol; 2006 Feb;29(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?
  • BACKGROUND: Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
  • Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
  • In this project, we examined the impact that participation in a randomized controlled trial of a multidisciplinary intervention designed to impact overall QOL had on fatigue for advanced cancer patients actively receiving treatment.
  • METHODS: Patients with newly diagnosed cancer were randomly assigned to an 8-session structured multidisciplinary intervention or a standard-care arm at the beginning of their course of radiotherapy (RT) designed to impact QOL.
  • Clinically, this structured multidisciplinary intervention had no impact on fatigue, and there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462503.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Wadhwa R, Ryu J, Gao R, Choi IK, Morrow G, Kaur K, Kim I, Kaul SC, Yun CO, Tanguay RM: Proproliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells. J Biol Chem; 2010 Feb 5;285(6):3833-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DmHsp22 expression in human cancer cells increased their malignant properties including anchorage-independent growth, tumor formation in nude mice, and resistance to a variety of anticancer drugs.

  • FlyBase. FlyBase .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Jun 2;474(2-3):159-64 [10838077.001]
  • [Cites] Exp Cell Res. 2003 May 15;286(1):96-101 [12729798.001]
  • [Cites] Methods Mol Biol. 2003;234:203-9 [12824533.001]
  • [Cites] FASEB J. 2004 Mar;18(3):598-9 [14734639.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):845-51 [15120040.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):597-601 [15122253.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2004 Sep;36(9):618-22 [15346199.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43382-5 [15331597.001]
  • [Cites] Int J Biol Markers. 1996 Jan-Mar;11(1):29-35 [8740639.001]
  • [Cites] Cell Mol Life Sci. 1997 Jan;53(1):104-13 [9117990.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29586-91 [9792667.001]
  • [Cites] Dev Biol. 1999 Mar 1;207(1):107-18 [10049568.001]
  • [Cites] J Pathol. 2005 Jan;205(1):74-81 [15532096.001]
  • [Cites] J Exp Biol. 2005 Feb;208(Pt 4):697-705 [15695762.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1659-69 [15879436.001]
  • [Cites] Ann Med. 2005;37(6):413-22 [16203614.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 25;337(3):1006-11 [16225851.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39373-9 [16176931.001]
  • [Cites] Proteomics. 2006 Feb;6(3):1038-48 [16385476.001]
  • [Cites] Cell Stress Chaperones. 2006 Spring;11(1):51-60 [16572729.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2973-80 [16425258.001]
  • [Cites] Am J Pathol. 2006 May;168(5):1526-30 [16651619.001]
  • [Cites] Cell Stress Chaperones. 2006 Summer;11(2):116-28 [16817317.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5377-90 [16619038.001]
  • [Cites] Arch Biochem Biophys. 2006 Oct 1;454(1):32-41 [16949546.001]
  • [Cites] FASEB J. 2006 Oct;20(12):2168-70 [16935933.001]
  • [Cites] Biotechnol Adv. 2007 Jul-Aug;25(4):385-95 [17459646.001]
  • [Cites] J Neurosci Res. 2007 Aug 1;85(10):2071-9 [17304582.001]
  • [Cites] J Biol Chem. 2007 Nov 23;282(47):34276-87 [17897943.001]
  • [Cites] J Neurosci Res. 2008 Feb 1;86(2):264-9 [17722063.001]
  • [Cites] Cell Stress Chaperones. 2007 Winter;12(4):307-19 [18229450.001]
  • [Cites] Mol Cell Proteomics. 2008 Feb;7(2):315-25 [17934217.001]
  • [Cites] Biotechnol J. 2008 Jun;3(6):728-39 [18446867.001]
  • [Cites] Cell Stress Chaperones. 2009 Jan;14(1):105-11 [18663603.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1711-9 [19411846.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1647-8 [19448434.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2000 Nov;55(11):B552-9 [11078089.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26753-61 [11342557.001]
  • [Cites] Exp Cell Res. 2001 Nov 15;271(1):161-8 [11697892.001]
  • [Cites] Prog Mol Subcell Biol. 2002;28:79-101 [11908067.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31204-10 [10896659.001]
  • (PMID = 19948727.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP-77796
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drosophila Proteins; 0 / Heat-Shock Proteins; 0 / Hsp22 protein, Drosophila; 0 / Mitochondrial Proteins; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; SH1WY3R615 / Nocodazole
  • [Other-IDs] NLM/ PMC2823525
  •  go-up   go-down


16. O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG: A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol; 2009 Feb;63(3):477-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
  • PURPOSE: To evaluate the safety, pharmacokinetics and determine the recommended dose of the selective apoptotic antineoplastic drug, OSI-461 administered on a twice-daily regimen to patients with advanced solid malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3961-8 [11358813.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):583-92 [11602670.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3100-4 [12374677.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):60-7 [16432163.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8442-7 [16166323.001]
  • [Cites] Biochem Pharmacol. 2002 Nov 1;64(9):1325-36 [12392815.001]
  • [Cites] Am J Clin Oncol. 2006 Aug;29(4):395-8 [16891869.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94 [12406645.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):611-6 [12479221.001]
  • [Cites] Pharmacogenetics. 2003 Jan;13(1):19-28 [12544509.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3454-61 [12972520.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4972-82 [14581372.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6710-21 [15475462.001]
  • [Cites] Cancer Res. 1976 Jan;36(1):60-6 [174814.001]
  • [Cites] J Clin Pharmacol. 1992 Dec;32(12):1089-95 [1487546.001]
  • [Cites] J Clin Pharmacol. 1993 Apr;33(4):381-6 [8473554.001]
  • [Cites] FEBS Lett. 1997 Jan 6;400(3):285-8 [9009215.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34263-71 [9852090.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70 [9861027.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):8-13 [9892175.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1999;135:67-104 [9932481.001]
  • [Cites] Exp Cell Res. 1999 Feb 25;247(1):38-47 [10047446.001]
  • [Cites] Crit Rev Clin Lab Sci. 1999 Aug;36(4):275-328 [10486703.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4559-63 [10493507.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7229-37 [15534096.001]
  • [Cites] Clin Pharmacokinet. 2004;43(15):1127-56 [15568891.001]
  • [Cites] Drug Metab Dispos. 2005 Jan;33(1):94-101 [15475413.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):336-50 [15526282.001]
  • [Cites] Br J Clin Pharmacol. 2005 Mar;59(3):355-64 [15752382.001]
  • [Cites] BJU Int. 2005 May;95(7):963-8 [15839914.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • (PMID = 18509645.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106349-05; United States / NCI NIH HHS / CA / K24 CA106349; United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / K24 CA106349-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 184SNS8VUH / Sulindac; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ NIHMS169572; NLM/ PMC2814254
  •  go-up   go-down


17. Mittal R, Perakath B, Chase S, Jesudason MR, Nayak S: Transanal excision of anorectal lesions--a single centre experience. Trop Gastroenterol; 2010 Jan-Mar;31(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into three groups. (1) Resection for benign disease (2) Curative and (3) Palliative resection for malignant disease.
  • RESULTS: Forty six patients underwent transanal excision, 21 for benign and 25 for malignant disease, 20 with curative and 5 with palliative intent.
  • Four patients with malignant melanoma and one with adenocarcinoma underwent palliative resection.
  • It offers good palliation of local symptoms in advanced malignant disease.
  • It can be used in a carefully selected group of patients with early rectal cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860237.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Parker KP, Bliwise DL, Ribeiro M, Jain SR, Vena CI, Kohles-Baker MK, Rogatko A, Xu Z, Harris WB: Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol; 2008 May 20;26(15):2464-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography.
  • PURPOSE: Sleep/wake disturbances are prevalent in patients with advanced cancer, but 24-hour polysomnography (PSG) examinations of these patterns have not been undertaken.
  • PATIENTS AND METHODS: The sample included patients with advanced cancer (solid tumors); those with neurologic disorders or psychosis, substance abuse, or brain metastasis were excluded.
  • Cancer type and selected medications may be risk factors for disturbed sleep and waking.


19. Zeisser-Labouèbe M, Delie F, Gurny R, Lange N: Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases. Eur J Pharm Biopharm; 2009 Feb;71(2):207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The high recurrence and lethality of ovarian cancer at advanced stages is problematic, especially due to the development of numerous micrometastases scattered throughout the abdominal cavity.
  • Fluorescence photodetection (PD) used in combination with surgical resection of malignant tissues has been suggested to improve recovery.
  • Based on promising in vivo results for the detection of bladder cancer, hypericin (Hy), a natural photosensitizer (PS), stands as a good candidate for the photodetection of ovarian cancer.
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Delivery Systems. Endoscopy. Female. Fluorescence. Injections, Intravenous. Lactic Acid / chemistry. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Polymers / chemistry. Rats. Rats, Inbred F344. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18977296.001).
  • [ISSN] 1873-3441
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Polymers; 26100-51-6 / poly(lactic acid); 33X04XA5AT / Lactic Acid; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


20. Bhurgri Y, Bhurgri H, Pervez S, Kayani N, Usman A, Bashir I, Bhurgri A, Hasan SH, Zaidi SM: Epidemiology of soft tissue sarcomas in Karachi South, Pakistan (1995-7). Asian Pac J Cancer Prev; 2008 Oct-Dec;9(4):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Epidemiological data of 96 (63 male and 33 female) incident STS cases registered at Karachi Cancer Registry (KCR) for Karachi South (KS), from 1st January 1995 to 31st December 1997, were reviewed.
  • Rhabdomyosarcomas and Ewing's sarcomas were more frequent in children and adolescents whereas fibrosarcomas, leiomyosarcomas, liposarcomas, malignant fibrous histiocytomas (MFHs) and schwannomas were encountered in the elderly.
  • CONCLUSION: Karachi falls into a high risk region for STS, observed in a relatively younger population, with a male predominance, high frequency of rhabdomyosarcoma and advanced stage at diagnosis.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Developing Countries. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Prevalence. Prognosis. Registries. Retrospective Studies. Sex Distribution. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256764.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


21. Jassem E, Górecka D, Krakowiak P, Kozielski J, Słomiński JM, Krajnik M, Fal AM: [Integrated care for patients with advanced chronic obstructive pulmonary disease]. Pneumonol Alergol Pol; 2010;78(2):126-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Integrated care for patients with advanced chronic obstructive pulmonary disease].
  • Advanced COPD usually leads to physical and mental deterioration, the patients often manage with the problems caused by the disease and other comorbidities poorly.
  • However, it seems that introducing an integrated approach proposed by World Health Organization, could improve the situation of advanced COPD patients.
  • In Poland, this kind of care has been provided in advanced cancer patients throughout stationary palliative care units and hospices during the last several years.


22. Healy R: Effectiveness of two opioid antagonists in treating opioid-induced constipation. Br J Nurs; 2009 Sep 10-23;18(16):998-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: This literature review reports the effectiveness of two peripheral opioid antagonists to relieve constipation caused by prolonged use of opioids, primarily in patients with advanced cancer.

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. NALTREXONE .
  • Hazardous Substances Data Bank. NALOXONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773693.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 0 / Narcotics; 0 / Quaternary Ammonium Compounds; 36B82AMQ7N / Naloxone; 5S6W795CQM / Naltrexone; 83387-25-1 / methylnaltrexone
  • [Number-of-references] 28
  •  go-up   go-down


23. Miyanishi K, Ishiwatari H, Hayashi T, Takahashi M, Kawano Y, Takada K, Ihara H, Okuda T, Takanashi K, Takahashi S, Sato Y, Matsunaga T, Homma H, Kato J, Niitsu Y: A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol; 2008 Apr;38(4):268-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
  • BACKGROUND: We previously reported that arterial infusion chemotherapy improved the response rate and survival of the patients with pancreatic cancer at advanced stages in an open trial.
  • We conducted a Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer after vascular supply distribution via superselective embolization.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375446.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Phipps E, Harris D, Braitman LE, Tester W, Madison-Thompson N, True G: Who enrolls in observational end of life research? Report from the cultural variations in approaches to end of life study. J Palliat Med; 2005 Feb;8(1):115-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To compare consenting advanced cancer patient participants and refusers in observational end of life research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662180.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Grant] United States / NINR NIH HHS / NR / R21 NR05112-02
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Oki E, Kakeji Y, Ohgaki K, Saeki K, Morita M, Emi Y, Maehara Y: [Impact of single nucleotide polymorphisms in glutathione S transferase gene GSTP1 in the treatment with oxaliplatin based chemotherapy]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1094-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxaliplatin has been the main treatment of choice in colorectal cancer in advanced settings.


26. Ivanov S: [Malignant ovarian cancer: conservative treatment and quality of life in young patients]. Akush Ginekol (Sofiia); 2008;47(5):11-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant ovarian cancer: conservative treatment and quality of life in young patients].
  • AIM: Our aim was to summarise our and foreign experience in the field of conservative treatment in patients with malignant ovarian tumors.
  • MATERIAL AND METHODS: We tried to evaluate the 10 years experience of our and foreign practice and expertise in conservative treatment of relatively young patients with ovarian cancer.
  • 22 patients were evaluated--all treated conservatively because of malignant ovarian tumors (early stage I as well as advanced tumor processes--stage II and stage III).
  • 18 patients were stage I and 4 in advanced stage.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infertility, Female / prevention & control. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227771.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


27. Nakai N, Asai J, Ueda E, Takenaka H, Katoh N, Kishimoto S: Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol; 2006 Jul;33(7):462-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells.
  • We performed a clinical trial to assess the feasibility and efficacy of immunotherapy with peptides, tumor lysate or both peptides and tumor lysate-pulsed mature, monocyte-derived dendritic cells (DC) for advanced malignant melanoma patients that are resistant to conventional therapies.
  • At the same time, cancer immunoediting of the tumor was also found.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / therapeutic use. Asian Continental Ancestry Group. Female. Humans. Male. Middle Aged. Peptides / immunology. Peptides / therapeutic use. Tissue Extracts / immunology. Tissue Extracts / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848818.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Peptides; 0 / Tissue Extracts
  •  go-up   go-down


28. Rose JH, Bowman KF, Radziewicz RM, Lewis SA, O'Toole EE: Predictors of engagement in a coping and communication support intervention for older patients with advanced cancer. J Am Geriatr Soc; 2009 Nov;57 Suppl 2:S296-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of engagement in a coping and communication support intervention for older patients with advanced cancer.
  • OBJECTIVES: To examine patterns and predictors of engagement in a coping and communication support (CCS) intervention tailored to the preferences of middle-aged and older patients in the early treatment phase for late-stage cancer.
  • DESIGN: Randomized controlled trial examining processes and outcomes of a CCS intervention for patients with late-stage cancer over time.
  • SETTING: Two ambulatory cancer clinics providing care for underserved populations in Cleveland.
  • African-American patients (P=.007) and those with a higher blunting style (P<.01), reporting more family discord in cancer communication (P=.009), and receiving fewer active cancer treatments (P=.008) were more engaged in the CCS intervention in the initial months.
  • Such interventions may be especially important to patients using more avoidant behaviors, experiencing more family discord communicating about cancer, or receiving fewer aggressive treatments in the early treatment phase for late-stage cancer.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20122033.001).
  • [ISSN] 1532-5415
  • [Journal-full-title] Journal of the American Geriatrics Society
  • [ISO-abbreviation] J Am Geriatr Soc
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


29. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A, Jäger E: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer; 2007 Jul 16;97(2):177-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
  • Altered histone deacetylase (HDAC) activity has been identified in several types of cancer.
  • This study was designed to determine the safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Mol Med. 2000 Aug;6(8):623-44 [11055583.001]
  • [Cites] Cell Mol Life Sci. 2001 May;58(5-6):728-36 [11437234.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36734-41 [11473107.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):477-83 [11673688.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] EMBO J. 2003 Jul 1;22(13):3411-20 [12840003.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1141-9 [14871994.001]
  • [Cites] Curr Opin Genet Dev. 1998 Apr;8(2):173-8 [9610407.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):40-8 [10072350.001]
  • [Cites] Prog Neurobiol. 1999 May;58(1):31-59 [10321796.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1383-9 [15585556.001]
  • [Cites] Leuk Res. 2005 Jul;29(7):739-48 [15927669.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2717-25 [16294345.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):112-9 [16323176.001]
  • [Cites] J Chemother. 2006 Aug;18(4):415-20 [17024798.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):1-16 [10825229.001]
  • (PMID = 17579623.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Repressor Proteins; 614OI1Z5WI / Valproic Acid; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC2360302
  •  go-up   go-down


30. Lo C, Walsh A, Mikulincer M, Gagliese L, Zimmermann C, Rodin G: Measuring attachment security in patients with advanced cancer: psychometric properties of a modified and brief Experiences in Close Relationships scale. Psychooncology; 2009 May;18(5):490-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring attachment security in patients with advanced cancer: psychometric properties of a modified and brief Experiences in Close Relationships scale.
  • OBJECTIVE: Attachment security has been identified as an important buffer of distress in patients with cancer and other medical illnesses but current measures have not been adapted for this population who may be older, in long-term stable relationships, and suffering from considerable disease burden.
  • Patients with metastatic gastrointestinal (GI) and lung cancer completed the ECR-M36 and other scales tapping self-esteem, social support, and depressive symptoms on two occasions within a period of 4-6 months.
  • [MeSH-major] Depression / etiology. Interpersonal Relations. Neoplasm Staging. Neoplasms / pathology. Neoplasms / psychology. Object Attachment. Surveys and Questionnaires


31. Davies EA, Sehgal A, Linklater KM, Heaps K, Moren C, Walford C, Cook R, Møller H: Cancer in the London prison population, 1986-2005. J Public Health (Oxf); 2010 Dec;32(4):526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer in the London prison population, 1986-2005.
  • BACKGROUND: Little research has investigated cancer care in UK prisons.
  • We wished to identify the number of new cases and the most common cancer diagnoses occurring each year in London prisoners, and the place of death for those who died from their disease.
  • METHODS: Using the database of the Thames Cancer Registry, we identified cancer diagnoses in residents of seven London prisons from 1986 to 2005 and the place of death of patients dying from their disease between 1996 and 2005.
  • RESULTS: On average, 31 patients were recorded as diagnosed with cancer while in prison within each 5-year period.
  • In women, 83% (85/102) of diagnoses were in situ carcinoma of the cervix, and in men, 19% (11/57) were of lung cancer.
  • CONCLUSIONS: London prisons contribute a small number of patients each year who require NHS cancer care, including those with advanced cancer who are released before death.
  • Future studies should investigate cancer incidence for the national prison population, methods for improving screening coverage and follow-up, the timeliness of access to cancer treatments and end-of-life care, and prisoners' and health professionals' experiences of care.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202981.001).
  • [ISSN] 1741-3850
  • [Journal-full-title] Journal of public health (Oxford, England)
  • [ISO-abbreviation] J Public Health (Oxf)
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R: Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol; 2009 Jul;84(7):408-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.
  • Venous thromboembolism (VTE) is common in patients with advanced cancer and may influence patient eligibility for clinical studies, quality of life, and survival.
  • Anderson Cancer Center to determine the frequency of VTE, associated characteristics, and clinical outcomes.
  • Multivariate analysis demonstrated that a history of VTE (P < 0.0001), pancreatic cancer (P = 0.007), and platelet count >440 x 10(9)/L (P = 0.026) predicted new VTE episodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437507.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR024148
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Koyyalagunta D, Burton AW: The role of chemical neurolysis in cancer pain. Curr Pain Headache Rep; 2010 Aug;14(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemical neurolysis in cancer pain.
  • Pain continues to be a significant symptom burden in cancer patients, with prevalence in 53% of patients at all stages of cancer and as high as 58% to 69% in those with advanced cancer.
  • Neurolytic blocks are a mainstay in the armamentarium of cancer pain management, more so in intractable pain from advanced cancer.
  • Here we discuss the use of various neurolytic blocks for cancer pain and detail some of the recent literature and our experience.

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHENOL .
  • Hazardous Substances Data Bank. SODIUM PHENOLATE .
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2007 Sep;18(9):1437-49 [17355955.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):277-81 [15942158.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Anesthesiology. 1988 Dec;69(6):989-93 [3195775.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1501-2 [18020918.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):850-6 [3802043.001]
  • [Cites] Clin J Pain. 1990 Dec;6(4):291-6 [2135029.001]
  • [Cites] Tumori. 2002 May-Jun;88(3):243-5 [12195764.001]
  • [Cites] J Neurosurg. 1988 Jul;69(1):39-45 [2454304.001]
  • [Cites] Pain Pract. 2008 Mar-Apr;8(2):98-109 [18366465.001]
  • [Cites] Cancer Control. 2000 Mar-Apr;7(2):142-8 [10783818.001]
  • [Cites] J Palliat Med. 2008 Nov;11(9):1195-9 [19021480.001]
  • [Cites] Clin J Pain. 2006 Jul-Aug;22(6):544-7 [16788341.001]
  • [Cites] Anesth Analg. 2008 Oct;107(4):1390-2 [18806057.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):430-8 [17100960.001]
  • [Cites] Pain Pract. 2007 Mar;7(1):27-30 [17305675.001]
  • [Cites] J Anesth. 2005;19(4):328-32 [16261474.001]
  • [Cites] Anesth Analg. 2010 Jan 1;110(1):216-9 [19910618.001]
  • [Cites] Ann Surg. 1993 May;217(5):447-55; discussion 456-7 [7683868.001]
  • [Cites] Orv Hetil. 1994 Jan 23;135(4):181-4 [8290243.001]
  • [Cites] Anesth Analg. 1985 Dec;64(12):1205-7 [4061904.001]
  • [Cites] Lancet. 1955 Jan 1;268(6853):18-20 [13222840.001]
  • [Cites] Reg Anesth. 1992 May-Jun;17(3):166-70 [1606100.001]
  • [Cites] JAMA. 2004 Mar 3;291(9):1092-9 [14996778.001]
  • [Cites] Anaesth Intensive Care. 2008 Sep;36(5):732-5 [18853596.001]
  • [Cites] Pain Pract. 2001 Jun;1(2):171-82 [17129293.001]
  • [Cites] Pain Physician. 2007 Nov;10 (6):757-63 [17987098.001]
  • [Cites] J Support Oncol. 2009 May-Jun;7(3):83-7, 90 [19507453.001]
  • [Cites] Otolaryngol Clin North Am. 2009 Feb;42(1):143-59, x [19134497.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2003 Sep;17(3):407-28 [14529011.001]
  • [Cites] Gastrointest Endosc. 1996 Dec;44(6):656-62 [8979053.001]
  • [Cites] Anesthesiology. 1990 Aug;73(2):236-9 [2382849.001]
  • (PMID = 20524161.001).
  • [ISSN] 1534-3081
  • [Journal-full-title] Current pain and headache reports
  • [ISO-abbreviation] Curr Pain Headache Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 339NCG44TV / Phenol; 3K9958V90M / Ethanol; PDC6A3C0OX / Glycerol
  •  go-up   go-down


34. Kavalerchik E, Goff D, Jamieson CH: Chronic myeloid leukemia stem cells. J Clin Oncol; 2008 Jun 10;26(17):2911-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although rare, chronic myeloid leukemia (CML) represents an important paradigm for understanding the molecular events leading to malignant transformation of primitive hematopoietic progenitors.
  • CML was the first cancer to be associated with a defined genetic abnormality, BCR-ABL, that is necessary and sufficient for initiating chronic phase disease as well as the first cancer to be treated with molecular targeted therapy.
  • Malignant progenitors or leukemia stem cells (LSCs) evolve as a result of both epigenetic and genetic events that alter hematopoietic progenitor differentiation, proliferation, survival, and self-renewal.
  • On subverting developmental processes normally responsible for maintaining robust life-long hematopoiesis, the LSCs are able to evade the majority of current cancer treatments that target rapidly dividing cells.
  • Combined therapies targeting aberrant properties of LSC may obviate therapeutic resistance and relapse in advanced phase and therapeutically recalcitrant CML.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Differentiation. Cell Proliferation. Cell Survival. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / metabolism. Gene Expression Regulation, Leukemic. Humans. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Secondary Prevention


35. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM: A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res; 2009 Sep 1;15(17):5569-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
  • PURPOSE: Systemic chemotherapy fails to access much of the tumor burden in patients with advanced cancer, significantly limiting its efficacy.
  • EXPERIMENTAL DESIGN: A phase I clinical study of escalating doses of the HER TKI lapatinib given as a 2-day pulse before a weekly infusion of nab-paclitaxel (100 mg/m(2)) was conducted in patients with advanced solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Circ Res. 2002 Jun 28;90(12):1243-50 [12089061.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):929-38 [12213721.001]
  • [Cites] Radiology. 2003 Dec;229(3):885-92 [14576446.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(3):285-92 [14755613.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75 [16896930.001]
  • [Cites] J Magn Reson Imaging. 2007 Dec;26(6):1618-25 [17968965.001]
  • [Cites] Neoplasia. 2007 Dec;9(12):1066-77 [18084614.001]
  • [Cites] Growth Factors. 2007 Aug;25(4):253-63 [18092233.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Neoplasia. 2008 May;10(5):489-500 [18472966.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3051-6 [18565892.001]
  • [Cites] Cell Signal. 2008 Oct;20(10):1804-14 [18627789.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2999-3005 [18458039.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2112-5 [8616858.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47 [9262252.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1454-7 [10197613.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):241-8 [10453726.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):330-5 [10496361.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] Pharm Res. 2005 Jun;22(6):867-74 [15948030.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7785-93 [16258082.001]
  • [Cites] Exp Cell Res. 2006 Feb 1;312(3):289-98 [16337626.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2173-80 [16489018.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18 [11345647.001]
  • (PMID = 19706807.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122216-01A1; United States / NCI NIH HHS / CA / CA122216-03; United States / NCI NIH HHS / CA / CA122216-01A1; United States / NCI NIH HHS / CA / R01 CA122216-02; United States / NCI NIH HHS / CA / R01 CA122216-03; United States / NCI NIH HHS / CA / R01 CA122216; United States / NCI NIH HHS / CA / CA122216-02
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS263170; NLM/ PMC3029022
  •  go-up   go-down


36. Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, Jotereau F, Dreno B, Labarrière N: Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother; 2007 Apr;56(4):515-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adoptive therapy of cancer has been mostly tested in advanced cancer patients using tumor-infiltrating lymphocytes (TIL).
  • We had performed a phase II/III randomised trial on 88 stage III melanoma patients, who received autologous TIL plus IL-2 or IL-2 alone, after complete tumour resection.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunotherapy, Adoptive. Lymphocytes, Tumor-Infiltrating / transplantation. Melanoma / therapy. Neoplasm Proteins / immunology. T-Lymphocytes / transplantation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874485.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


37. von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, Sarbia M: Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog; 2006 Oct;45(10):786-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
  • A series of 123 primary resected adenocarcinomas of the distal esophagus, arising in association with Barrett's esophagus, and corresponding normal squamous epithelium (n = 12) and non-malignant Barrett's mucosa (n = 11), were investigated by means of quantitative RT-PCR for expression of TGF-beta1, using paraffin embedded tissue samples.
  • Relative overexpression of the TGF-beta1 gene was associated with advanced UICC stage (III/IV vs. I/II; P = 0.009), depth of tumor infiltration (pT3 vs. pT1/2; P < 0.001), nodal involvement (pN1 vs. pN0; P = 0.006), and lymphatic vessel invasion (L1 vs. L0; P = 0.011).
  • Our data show that TGF-beta1 overexpression is associated with advanced stage of esophageal adenocarcinoma and implies a negative impact on survival.
  • The TGF-beta pathway may be a potential target for molecular therapies of advanced tumors of this entity.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barrett Esophagus / genetics. Barrett Esophagus / pathology. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Transforming Growth Factor beta1

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921482.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


38. Badr H, Laurenceau JP, Schart L, Basen-Engquist K, Turk D: The daily impact of pain from metastatic breast cancer on spousal relationships: a dyadic electronic diary study. Pain; 2010 Dec;151(3):644-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The daily impact of pain from metastatic breast cancer on spousal relationships: a dyadic electronic diary study.
  • Women with metastatic breast cancer (MBC) experience high levels of emotional distress and pain.
  • Although individuals often rely on their intimate partners to provide physical and emotional support when they are in pain, the daily impact of pain on the spousal relationship in the context of advanced cancer is unclear.
  • Patients and partners rated the patient's pain, their own mood (circumplex adjectives), the provision/receipt of social support, and the degree to which cancer interfered with their relationship.


39. Koczwara B: Addressing fertility needs of breast cancer patients: oncology perspective. Expert Rev Anticancer Ther; 2008 Aug;8(8):1323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addressing fertility needs of breast cancer patients: oncology perspective.
  • Premenopausal women represent approximately 23% of women diagnosed with breast cancer.
  • As the medial age of first pregnancy increases in developed countries, a greater proportion of women are diagnosed with breast cancer at a time when they have not yet completed their family.
  • For these women, the impact of breast cancer treatment on their reproductive capacity can be of significant concern and may influence their treatment decisions.
  • Despite these concerns only a proportion of premenopausal women with breast cancer are informed about their treatment choices in light of their reproductive needs.
  • The diagnosis of cancer itself as well as systemic cancer treatments, including chemotherapy and hormonal therapy, can delay and/or reduce the reproductive capacity.
  • Special fertility considerations are required in women with family history and/or evidence of genetic predisposition to breast cancer as strategies for risk reduction may impact on their fertility choices.
  • Finally, as survival of women with metastatic breast cancer increases, women with advanced cancer who become pregnant pose unique management challenges for oncologists and obstetricians alike.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699768.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


40. Soerjomataram I, Louwman WJ, Lemmens VE, Coebergh JW, de Vries E: Are patients with skin cancer at lower risk of developing colorectal or breast cancer? Am J Epidemiol; 2008 Jun 15;167(12):1421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are patients with skin cancer at lower risk of developing colorectal or breast cancer?
  • Ultraviolet exposure may reduce the risk of colorectal and breast cancer as the result of rising vitamin D levels.
  • Because skin cancer is positively related to sun exposure, the authors hypothesized a lower incidence of breast and colorectal cancer after skin cancer diagnosis.
  • They analyzed the incidence of colorectal and breast cancer diagnosed from 1972 to 2002 among 26,916 Netherlands skin cancer patients (4,089 squamous cell carcinoma (SCC), 19,319 basal cell carcinoma (BCC), and 3,508 cutaneous malignant melanoma (CMM)).
  • A markedly decreased risk of colorectal cancer was found for subgroups supposedly associated with the highest accumulated sun exposure: men (standardized incidence ratio (SIR) = 0.83, 95% confidence interval (CI): 0.71, 0.97); patients with SCC (SIR = 0.64, 95% CI: 0.43, 0.93); older patients at SCC diagnosis (SIR = 0.59, 95% CI: 0.37, 0.88); and patients with a SCC or BCC lesion on the head and neck area (SIR = 0.59, 95% CI: 0.36, 0.92 for SCC and SIR = 0.78, 95% CI: 0.63, 0.97 for BCC).
  • Patients with CMM exhibited an increased risk of breast cancer, especially advanced breast cancer (SIR = 2.20, 95% CI: 1.10, 3.94) and older patients at CMM diagnosis (SIR = 1.87, 95% CI: 1.14, 2.89).
  • Study results suggest a beneficial effect of continuous sun exposure against colorectal cancer.
  • The higher risk of breast cancer among CMM patients may be related to socioeconomic class, both being more common in the affluent group.


41. Lethborg C, Aranda S, Cox S, Kissane D: To what extent does meaning mediate adaptation to cancer? The relationship between physical suffering, meaning in life, and connection to others in adjustment to cancer. Palliat Support Care; 2007 Dec;5(4):377-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] To what extent does meaning mediate adaptation to cancer? The relationship between physical suffering, meaning in life, and connection to others in adjustment to cancer.
  • OBJECTIVES: This study builds on previous work that explored the lived experience of meaning in advanced cancer.
  • The aims were to explore the associations of suffering (physical and existential distress) and coping (via social support) with psychological distress and global meaning using a battery of instruments among adults attending an Australian metropolitan cancer service (n=100).
  • On the basis of this study, it is concluded that the factors related to suffering clearly promote psychological distress, and the reverse is true for global meaning for those living with cancer.
  • SIGNIFICANCE OF RESULTS: This study speaks to the clinical complexity of the dynamic experience of suffering and meaning in cancer.


42. Dehghan R, Ramakrishnan J, Ahmed N, Harding R: The use of morphine to control pain in advanced cancer: an investigation of clinical usage in Bangladesh. Palliat Med; 2010 Oct;24(7):707-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of morphine to control pain in advanced cancer: an investigation of clinical usage in Bangladesh.
  • In 2007, 13% of all deaths worldwide were due to cancer, and of these 72% occurred in low- and middle-income countries.
  • This paper reports data from a cross-sectional survey that aimed to investigate the use of morphine in advanced cancer in palliative care setting in Bangladesh, in order to inform clinical practice and fledgling service development.
  • Cancer patients, family members and palliative care specialists (20 in total) were interviewed in two medical settings.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20671007.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


43. Noble SI, Hood K, Finlay IG: The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med; 2007 Sep;21(6):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
  • The advantages of low-molecular weight heparin (LMWH) over warfarin, in the treatment of cancer associated venous thromboembolism (VTE) are well reported.
  • We report a case series of 62 patients with advanced malignancy and VTE treated with long-term LMWH according to either the CLOT (full dose) or Montreal (reduced dose) regime.
  • No patients developed evidence of heparin-induced thrombocytopenia or osteoporosis.Long-term LMWH appears effective in treatment of VTE in the palliative care population with advanced cancer.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846086.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


44. Kaneko M: Changes and current state of diagnosis of lung cancer after development of the flexible bronchofiberscope. Jpn J Clin Oncol; 2010 Sep;40(9):838-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes and current state of diagnosis of lung cancer after development of the flexible bronchofiberscope.
  • The flexible bronchofiberscope developed by Ikeda et al. has brought about revolutionary changes in the diagnosis and treatment of lung cancer.
  • Bronchoscopy is also used for the treatment of early hilar lung cancer, and in patients with airway stenosis due to advanced cancer, laser therapy, brachytherapy, and stenting can be performed.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736220.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Lee HS, Yang HK, Kim WH, Choe G: Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers. Cancer Res Treat; 2005 Apr;37(2):98-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: To investigate the possible relationship between the clinico-pathologic characteristics and the survival of gastric cancer patients, the expression status of DNA-PKcs was determined in 279 consecutive gastric cancers.
  • The loss of DNA-PKcs expression was significantly associated with advanced cancer (p<0.001), lymphatic invasion (p=0.001), lymph node metastasis (p=0.009), and advanced pTNM stage (p=0.009).
  • Moreover, the loss of DNA-PKcs expression was identified to correlate with a lower survival in the subgroup of stage I gastric cancer patients (p=0.037).
  • CONCLUSION: The loss of DNA-PKcs expression was found in 23% of human gastric cancers and this was identified to significantly correlate with poor patient survival, especially for stage I gastric cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1403-8 [9990036.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2237-46 [11147594.001]
  • [Cites] Genomics. 1998 Jan 1;47(1):71-83 [9465298.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):525-30 [9435225.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):609-14 [9430651.001]
  • [Cites] EMBO J. 1997 Aug 15;16(16):5098-112 [9305651.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5013-6 [9371494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10285-90 [8816792.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):8936-41 [8621537.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1183-5 [7855602.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6904-8 [8041718.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] J Pathol. 2002 Sep;198(1):21-9 [12210059.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8381-4 [11731412.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2084-90 [11264175.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1551-9 [9512523.001]
  • (PMID = 19956487.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785401
  • [Keywords] NOTNLM ; DNA-PKcs / Immunohistochemistry / Stomach neoplasms / Survival analysis
  •  go-up   go-down


46. Ihedioha U, Alani A, Modak P, Chong P, O'Dwyer PJ: Hernias are the most common cause of strangulation in patients presenting with small bowel obstruction. Hernia; 2006 Aug;10(4):338-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were seven deaths; three occurred in patients declared unfit for surgery, while four occurred post-operatively - two had strangulated bowel, the other two had advanced cancer.

  • MedlinePlus Health Information. consumer health - Hernia.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2000 Jul;180(1):33-6 [11036136.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):193-201 [15273540.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):313-5 [9988792.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):788-92 [15379812.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1240-7 [10971435.001]
  • [Cites] Eur J Surg. 1997 Mar;163(3):169-74 [9085057.001]
  • [Cites] ANZ J Surg. 2004 Nov;74(11):1010-2 [15550093.001]
  • [Cites] J Am Coll Surg. 1996 Oct;183(4):297-306 [8843257.001]
  • (PMID = 16761112.001).
  • [ISSN] 1265-4906
  • [Journal-full-title] Hernia : the journal of hernias and abdominal wall surgery
  • [ISO-abbreviation] Hernia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Førde R, Kongsgaard U, Aasland OG: [Palliative sedation to the dying]. Tidsskr Nor Laegeforen; 2006 Feb 9;126(4):471-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ten of the 12 treatments which were registered in detail concerned patients with advanced cancer and in great discomfort.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477288.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Hypnotics and Sedatives; 76I7G6D29C / Morphine; R60L0SM5BC / Midazolam
  •  go-up   go-down


48. Rodriguez KL, Bayliss N, Alexander SC, Jeffreys AS, Olsen MK, Pollak KI, Kennifer SL, Tulsky JA, Arnold RM: How oncologists and their patients with advanced cancer communicate about health-related quality of life. Psychooncology; 2010 May;19(5):490-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How oncologists and their patients with advanced cancer communicate about health-related quality of life.
  • OBJECTIVE: To describe the content and frequency of communication about health-related quality of life (HRQOL) during outpatient encounters between oncologists and their patients with advanced cancer.
  • CONCLUSIONS: HRQOL discussions between oncologists and patients are common, but the emphasis is often on treatment (e.g. side effects) and symptoms (e.g. pain) even in patients with advanced disease.
  • Given the often intense emotional experience of patients with advanced cancer, oncologists may need to pay more attention to psychological, social, and spiritual HRQOL concerns.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Talking With Your Doctor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] Semin Oncol. 1995 Apr;22(2 Suppl 3):73-81 [7537908.001]
  • [Cites] Patient Educ Couns. 1995 Jul;25(3):237-46 [7630827.001]
  • [Cites] Oncol Nurs Forum. 1995 Jul;22(6):957-64 [7567613.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):29-37 [9136939.001]
  • [Cites] Qual Life Res. 1997 Mar;6(2):151-8 [9161115.001]
  • [Cites] Cancer Pract. 1997 May-Jun;5(3):147-54 [9171550.001]
  • [Cites] Qual Life Res. 1998 Jan;7(1):85-91 [9481154.001]
  • [Cites] Cancer Nurs. 1998 Jun;21(3):151-61 [9615505.001]
  • [Cites] Acad Med. 1998 Sep;73(9):1003-5 [9759106.001]
  • [Cites] Palliat Med. 2006 Dec;20(8):813-9 [17148536.001]
  • [Cites] J Support Oncol. 2008 May-Jun;6(5):221-9, 233 [18551858.001]
  • [Cites] Clin Lung Cancer. 2008 Jul;9(4):206-12 [18650167.001]
  • [Cites] Support Care Cancer. 2008 Sep;16(9):1049-57 [18196288.001]
  • [Cites] J Am Geriatr Soc. 2000 May;48(5 Suppl):S110-21 [10809464.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1011-5 [11308246.001]
  • [Cites] Soc Sci Med. 2001 Jun;52(12):1865-78 [11352412.001]
  • [Cites] JAMA. 2002 Dec 18;288(23):3027-34 [12479768.001]
  • [Cites] Cancer Nurs. 2003 Oct;26(5):337-45 [14710794.001]
  • [Cites] Am J Public Health. 1976 Sep;66(9):847-53 [961952.001]
  • [Cites] J Health Soc Behav. 1976 Dec;17(4):329-39 [1010914.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] J Med Educ. 1982 Feb;57(2):105-12 [7057429.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S148-56 [2646487.001]
  • [Cites] World Health Organ Tech Rep Ser. 1990;804:1-75 [1702248.001]
  • [Cites] BMJ. 1990 Dec 22-29;301(6766):1407-8 [2279152.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3131-5 [1710541.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1833-8 [1453197.001]
  • [Cites] Cancer Invest. 1993;11(3):327-36 [8485655.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):336-41 [8004605.001]
  • [Cites] J Pain Symptom Manage. 1994 Apr;9(3):186-92 [8014530.001]
  • [Cites] CMAJ. 1995 May 1;152(9):1423-33 [7728691.001]
  • (PMID = 19449348.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-100387; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R01 CA100387-03S1; United States / NCI NIH HHS / CA / R01 CA100387-01; United States / NCI NIH HHS / CA / R01 CA100387; United States / NCI NIH HHS / CA / CA100387-03S1; United States / NCI NIH HHS / CA / CA100387-01; United States / NCI NIH HHS / CA / 3R01 CA-100387-03S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS282560; NLM/ PMC3090079
  •  go-up   go-down


49. Losanoff JE, Konrad A, Sauter ER: Breast cancer after severe burn injury: coincidence or consequence? Breast J; 2008 Jan-Feb;14(1):87-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer after severe burn injury: coincidence or consequence?
  • Malignant neoplasms arising in burn scars are well known but rarely encountered.
  • We discuss personal experience with two patients, both female, who were diagnosed with advanced breast cancer many years after severe thermal injury to their breasts.
  • Our experience, similar to the scant previously published data, reinforces that burn scars demand a high index of suspicion for the presence of an underlying malignant neoplasm.
  • The literature and our study suggest that breast cancer may occur after severe thermal injury.
  • Breast lesions in this or a similar clinical scenario should be considered malignant until proven otherwise, and a tissue diagnosis must be pursued without delay.


50. Tebben PJ, Kalli KR, Cliby WA, Hartmann LC, Grande JP, Singh RJ, Kumar R: Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc; 2005 Jun;80(6):745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated fibroblast growth factor 23 in women with malignant ovarian tumors.
  • PATIENTS AND METHODS: Between May 2002 and September 2003 at the Mayo Clinic in Rochester, Minn, plasma or serum FGF23 concentrations were measured in 39 healthy women and in 14 with benign ovarian tumors, 14 with early-stage ovarian cancer, and 13 with advanced-stage ovarian cancer.
  • Immunohistochemistry using anti-human FGF23 antibodies was performed on tissue from benign masses and advanced-stage tumors.
  • RESULTS: Serum or plasma FGF23 concentrations were significantly higher in women with advanced-stage ovarian cancer compared with concentrations in women with early-stage ovarian cancer or benign disease or in healthy women.
  • Serum iFGF23 and cFGF23 concentrations were positively correlated with serum phosphorus among women with ovarian cancer.
  • Immunohistochemistry detected FGF23 tissue staining in malignant ovarian cancer cells.
  • CONCLUSION: Serum or plasma FGF23 concentrations are elevated in patients with advanced-stage epithellal ovarian cancer without reductions in serum phosphate concentrations.
  • The presence of elevated FGF23 concentrations in patients with an ovarian mass should suggest advanced-stage disease.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948297.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK065830; United States / NIDDK NIH HHS / DK / DK 25409; United States / NIDDK NIH HHS / DK / DK 58546; United States / NIDDK NIH HHS / DK / DK 65830
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / fibroblast growth factor 23; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down


51. Sperti C, Berselli M, Pasquali C, Pastorelli D, Pedrazzoli S: Aggressive behaviour of solid-pseudopapillary tumor of the pancreas in adults: a case report and review of the literature. World J Gastroenterol; 2008 Feb 14;14(6):960-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solid-pseudopapillary tumor (SPT) is a rare neoplasm of the pancreas that usually occurs in young females.
  • It is generally considered a low-grade malignant tumor that can remain asymptomatic for several years.
  • The best treatment remains a radical resection whenever possible, even in locally advanced or metastatic disease.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):887-9 [10919054.001]
  • [Cites] J Surg Oncol. 2007 Jun 15;95(8):640-4 [17477365.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Pancreatology. 2002;2(5):495-8 [12378119.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Ann Chir. 2003 Oct;128(8):543-8 [14559306.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):193-8 [14991875.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):291-3 [15043751.001]
  • [Cites] J Surg Oncol. 1983 Feb;22(2):115-7 [6823124.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):272-5 [6830334.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2783-5 [4052952.001]
  • [Cites] Gastroenterol Jpn. 1987 Jun;22(3):379-84 [2442059.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):283-91 [2295051.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):763-70 [1812691.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):82-92 [8416730.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):433-6 [8457156.001]
  • [Cites] Med Pediatr Oncol. 1993;21(5):365-7 [8492753.001]
  • [Cites] Surgery. 1995 Nov;118(5):821-8 [7482268.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(10):789-93 [9587521.001]
  • [Cites] Pathol Int. 1999 Mar;49(3):231-4 [10338079.001]
  • [Cites] Cancer. 1961 Nov-Dec;14:1272-94 [13909709.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):185-6 [15737835.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1403-9 [15761986.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] Pancreatology. 2005;5(2-3):289-94 [15855828.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):456-9 [16109536.001]
  • [Cites] Pathol Int. 2005 Dec;55(12):792-6 [16287495.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):276-82 [16457845.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):733-7 [16609955.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1157-63 [16778826.001]
  • [Cites] Pancreatology. 2006;6(4):291-6 [16636602.001]
  • [Cites] JOP. 2006;7(6):635-42 [17095844.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):587-90 [17139438.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):639-40 [17149006.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):809-16 [17198473.001]
  • [Cites] JOP. 2007;8(2):223-7 [17356247.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):289-96 [11320522.001]
  • (PMID = 18240360.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687069
  •  go-up   go-down


52. Sugiyama T, Yoshizaki A, Hatayama S: [Ovarian cancer treatment from the standpoint of the gynecologic oncologist]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1011-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
  • Ovarian cancer treatment on the standpoint of the gynecologic oncologist: Ovarian cancer is comprehensively treated with combined surgery and anticancer chemotherapy, which influence each other.
  • In the initial surgery, a cancer stage is decided, and in advanced cancer, primary debulking surgery is conducted.
  • Improved diagnostic imaging such as PET enhances aggressive surgery for recurrent cancer.
  • [MeSH-minor] Bleomycin / administration & dosage. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Gynecologic Surgical Procedures / methods. Humans. Informed Consent. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Paclitaxel / administration & dosage. Survival Rate. Taxoids / administration & dosage. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637537.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; PVB protocol; TP protocol
  •  go-up   go-down


53. Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, Cai Y, Li D, Xu B: Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia; 2005 Nov;21(7):631-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases).
  • The study was to evaluate the efficacy of the Adp53 combined with hyperthermia on advanced cancer.
  • Fifteen patients with advanced cancer were enrolled in this clinical trial.
  • In conclusion, Adp53 combined with hyperthermia was safe and effective in patients with advanced cancer and p53 gene therapy was potential to thermosensitize in advanced cancer.
  • [MeSH-minor] Adenoviruses, Human / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Genes, p53. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304714.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


54. Alsaeed E: Avoidance of radiotherapy-related, gastrointestinal complications in a patient with systemic lupus erythematosus: a case report and review of literature. Saudi J Gastroenterol; 2009 Oct-Dec;15(4):268-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with active SLE and grade 4 nephropathy presented with inoperable advanced cancer of the cervix which proved to be contraindicated for chemotherapy.
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Radiation Dosage

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 1989 Jan;40(1):83-4 [2920524.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Sep;4(5):331-2 [1390352.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3744-52 [8490925.001]
  • [Cites] Autoimmunity. 1994;17(4):271-8 [7524704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):9-14 [19100920.001]
  • [Cites] Radiother Oncol. 2006 Feb;78(2):123-30 [16445999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):498-506 [18164848.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):648-53 [18506734.001]
  • [Cites] J Clin Immunol. 1995 Nov;15(6):284-92 [8576314.001]
  • (PMID = 19794275.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2981846
  •  go-up   go-down


55. Fu WP, Kam MH, Ling WM, Ong SF, Suzannah N, Eu KW: Screening for colorectal cancer using a quantitative immunochemical faecal occult blood test: a feasibility study in an Asian population. Tech Coloproctol; 2009 Sep;13(3):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for colorectal cancer using a quantitative immunochemical faecal occult blood test: a feasibility study in an Asian population.
  • BACKGROUND: The quantitative immunochemical faecal occult blood test (qFOBT) has been shown to be an accurate method of identifying significant colorectal neoplasia including cancer and advanced adenomas.
  • This study reports the results of a Singapore population-based colorectal cancer screening event using the qFOBT.
  • METHODS: This event was held as part of a colorectal cancer awareness exhibition.
  • All asymptomatic individuals above the age of 40 years with no previous colorectal cancer screening in the last 1 year were invited to participate.
  • Three participants had sigmoid cancer and 12 had advanced polyps, all of which were located distally in the sigmoid colon or rectum.
  • CONCLUSION: The qFOBT at a positive faecal haemoglobin threshold of 100 ng/ml has a high positive predictive value and is an effective screening tool for colorectal cancer in an Asian population.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. GUM GUAIAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] Ann Intern Med. 2007 Feb 20;146(4):244-55 [17310048.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1467-71 [8942774.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Cancer. 2003 May 15;97(10):2420-4 [12733140.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):218-21 [17211476.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):422-8 [16083699.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1331-8 [10811348.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2519-25 [16279909.001]
  • [Cites] ANZ J Surg. 2007 Jun;77(6):446-9 [17501884.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2499-507 [12385430.001]
  • [Cites] Gut. 2007 Feb;56(2):210-4 [16891354.001]
  • [Cites] Korean J Lab Med. 2007 Jun;27(3):210-5 [18094578.001]
  • [Cites] Gut. 2008 Aug;57(8):1166-76 [18628378.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2152-9 [16998938.001]
  • (PMID = 19629380.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 9000-29-7 / Guaiac
  •  go-up   go-down


56. Bañuelos CA, Banáth JP, Kim JY, Aquino-Parsons C, Olive PL: gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res; 2009 May 15;15(10):3344-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Is a similar approach feasible using biopsies from patients with cervical cancer?
  • Tumor biopsies were examined using 47 paraffin-embedded sections from untreated tumors and 24 sections from 8 patients undergoing radiochemotherapy for advanced cancer of the cervix.
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy. DNA, Neoplasm / metabolism. Dose-Response Relationship, Drug. Flow Cytometry. HCT116 Cells. Humans. Injections, Intraperitoneal. Mice. Mice, Inbred NOD. Mice, SCID. Microscopy, Fluorescence. Neoplasm, Residual / metabolism. Neoplasm, Residual / pathology. Neoplasm, Residual / therapy. Phosphorylation / drug effects. Phosphorylation / radiation effects. Time Factors. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2009 May 15;15(10):3241-3 [19447863.001]
  • (PMID = 19401347.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / H2AFX protein, human; 0 / Histones; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. O'Connor JP, Naish JH, Parker GJ, Waterton JC, Watson Y, Jayson GC, Buonaccorsi GA, Cheung S, Buckley DL, McGrath DM, West CM, Davidson SE, Roberts C, Mills SJ, Mitchell CL, Hope L, Ton NC, Jackson A: Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Ten patients with advanced cancer of the abdomen and pelvis underwent serial measurement of tumor R(1) while breathing medical air (21% oxygen) followed by 100% oxygen (oxygen-enhanced MRI).

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. OXYGEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327904.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601746; United Kingdom / Cancer Research UK / / C19221/A6086; United Kingdom / Cancer Research UK / / C21247/A7473; United Kingdom / Cancer Research UK / / C237/A6295
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium; S88TT14065 / Oxygen
  •  go-up   go-down


58. Rothman MD, Van Ness PH, O'Leary JR, Fried TR: Refusal of medical and surgical interventions by older persons with advanced chronic disease. J Gen Intern Med; 2007 Jul;22(7):982-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refusal of medical and surgical interventions by older persons with advanced chronic disease.
  • BACKGROUND: Patients with advanced chronic disease are frequently offered medical and surgical interventions with potentially large trade-offs between benefits and burdens.
  • OBJECTIVE: To assess the frequency of, reasons for, factors associated with, and outcomes of treatment refusal among older persons with advanced chronic disease.
  • PARTICIPANTS: Two hundred twenty-six community-dwelling persons with advanced cancer, chronic obstructive pulmonary disease, or congestive heart failure, interviewed at least every 4 months for up to 2 years.
  • CONCLUSIONS: Refusal of medical and surgical interventions other than medications is common among persons with advanced chronic disease, and is associated with a greater desire for, and understanding of, prognostic information.

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 22-29;282(24):2313-20 [10612318.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-152-W5-166 [15840625.001]
  • [Cites] Rheumatology (Oxford). 2002 Mar;41(3):253-61 [11934960.001]
  • [Cites] JAMA. 2002 Jul 24-31;288(4):462-7 [12132976.001]
  • [Cites] Am J Med. 2002 Aug 15;113(3):200-7 [12208378.001]
  • [Cites] Arthritis Rheum. 2002 Aug15;47(4):421-8 [12209490.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2002 Nov;57(6):S348-54 [12426443.001]
  • [Cites] Am Heart J. 2002 Dec;144(6):1052-6 [12486430.001]
  • [Cites] Arch Intern Med. 2004 Sep 13;164(16):1749-55 [15364667.001]
  • [Cites] Am J Public Health. 2004 Oct;94(10):1782-7 [15451750.001]
  • [Cites] Gerontologist. 1969 Autumn;9(3):179-86 [5349366.001]
  • [Cites] J Am Geriatr Soc. 1975 Oct;23(10):433-41 [1159263.001]
  • [Cites] J Clin Epidemiol. 1990;43 Suppl:11S-28S [2174967.001]
  • [Cites] J Am Geriatr Soc. 1992 Dec;40(12):1221-6 [1447438.001]
  • [Cites] J Am Geriatr Soc. 1994 Mar;42(3):303-7 [8120316.001]
  • [Cites] Ann Intern Med. 1995 Feb 1;122(3):191-203 [7810938.001]
  • [Cites] Ann Intern Med. 1996 Aug 15;125(4):284-93 [8678391.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1187-93 [9555758.001]
  • [Cites] JAMA. 1998 Jun 3;279(21):1709-14 [9624023.001]
  • [Cites] JAMA. 1963 Sep 21;185:914-9 [14044222.001]
  • [Cites] Arch Intern Med. 2004 Nov 22;164(21):2321-4 [15557410.001]
  • [Cites] Med Care. 2004 Nov;42(11):1056-65 [15586832.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):276-80 [16041219.001]
  • [Cites] Kidney Int. 2005 Sep;68(3):1282-8 [16105062.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1061-6 [11932474.001]
  • (PMID = 17483977.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / P30 AG21342; United States / NIA NIH HHS / AG / T32AG1934; United States / NIA NIH HHS / AG / K02 AG020113; United States / NIA NIH HHS / AG / AG019769-01A1; United States / NIA NIH HHS / AG / R01 AG019769; United States / PHS HHS / / R01 G19769; United States / NIA NIH HHS / AG / P30 AG021342; United States / NIA NIH HHS / AG / K02 AG020113-01; United States / NIA NIH HHS / AG / K02 AG20113; United States / NIA NIH HHS / AG / AG020113-01; United States / NIA NIH HHS / AG / R01 AG019769-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS28339; NLM/ PMC1948844
  •  go-up   go-down


59. Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA: A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol; 2007 Mar;59(4):467-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
  • METHODS: This was a phase I study where patients with advanced cancer were treated with escalating doses of gefitinib (1,000, 1,500, 2,250, 3,000 mg) on days 1 and 2 followed by docetaxel (75 mg/m2) on day 3 of a 21 day cycle.
  • RESULTS: 18 patients were enrolled in this study with the most frequent tumor types being non-small cell lung cancer and head and neck squamous cell cancer.
  • Partial responses were observed in one patient with head and neck squamous cell carcinoma and one patient with anaplastic thyroid cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896930.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; S65743JHBS / gefitinib
  •  go-up   go-down


60. Faried A, Faried LS, Usman N, Kato H, Kuwano H: Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol; 2007 Dec;14(12):3593-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rho GTPases are involved in the organization of a microfilament network, cell-to-cell interaction, and malignant transformation.
  • rhoA correlated with tumor differentiation and rhoC correlated with an advanced tumor, node, metastasis system classifications. rhoA and rhoC in ESCC showed a positive correlation (P = .008).
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896152.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 124671-05-2 / RHOA protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


61. Suzuki M, Ando S, Iida T, Fujisawa T, Kimura H: Multimodality therapy and significance of serum CYFRA21-1 for thymic carcinoma. Oncol Rep; 2005 Jun;13(6):1127-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymic carcinoma is a rare mediastinal neoplasm with a poor prognosis due to delayed diagnosis and highly malignant behavior.
  • Stage may provide a basis for prognosis in stage III-IVb thymic carcinoma, and resection is one of the most important parts of multimodality treatment for advanced thymic carcinoma.
  • [MeSH-major] Antigens, Neoplasm / blood. Thymoma / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease Progression. Female. Humans. Keratin-19. Keratins. Male. Mediastinal Neoplasms / blood. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870932.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


62. Stein A, Voigt W, Jordan K: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol; 2010 Jan;2(1):51-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diarrhea is one of the main drawbacks for cancer patients.
  • Chemotherapy-induced diarrhea (CID) is a common problem, especially in patients with advanced cancer.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5248-53 [18768432.001]
  • [Cites] Cancer Biol Ther. 2008 Dec;7(12):1919-25 [18927500.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Dec;5(12):682-96 [18941434.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jun;64(1):123-32 [18998135.001]
  • [Cites] Clin Colorectal Cancer. 2009 Jan;8(1):11-4 [19203891.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2604-14 [19349540.001]
  • [Cites] Curr Opin Support Palliat Care. 2009 Mar;3(1):31-5 [19365159.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):757-63 [19615940.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1988 Jul-Aug;12(4):325-31 [3138440.001]
  • [Cites] Clin Colorectal Cancer. 2004 May;4(1):46-50 [15207020.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1296 [15277273.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 [12165641.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5778-84 [12384538.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1637-47 [12668652.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1669-74 [12721240.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1382-8 [15007088.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):388-94 [15160289.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2918-26 [15254061.001]
  • [Cites] Am J Health Syst Pharm. 1998 Aug 1;55(15):1573-80 [9706182.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3169-78 [9738589.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(4):280-6 [9744772.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3499-505 [9858931.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Jan;232(1):96-106 [17202590.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1011-6 [17350823.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92(11):1962-75 [9362174.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):711-4 [9384471.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1049-51 [9402181.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1695-9 [9563485.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):859-60 [9644701.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2745-51 [9704727.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):953-61 [12476290.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Sep;18(9):1095-100 [12911669.001]
  • [Cites] Oral Microbiol Immunol. 2003 Oct;18(5):278-84 [12930518.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):648-57 [14966087.001]
  • [Cites] Semin Oncol Nurs. 2004 Feb;20(1):38-47 [15038516.001]
  • [Cites] Support Care Cancer. 2004 Aug;12(8):561-70 [15160318.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):709-15 [8622015.001]
  • [Cites] Oncologist. 2000;5(3):250-9 [10884503.001]
  • [Cites] Gut. 2000 Nov;47(5):632-7 [11034578.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1136-41 [11350876.001]
  • [Cites] Support Care Cancer. 2001 Jun;9(4):258-60 [11430421.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1251-3 [10586346.001]
  • [Cites] Support Care Cancer. 2000 Jan;8(1):65-7 [10650901.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Gut. 2001 Jan;48(1):28-33 [11115819.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):227-9 [11300329.001]
  • [Cites] Pharmacogenomics J. 2002;2(1):43-7 [11990381.001]
  • [Cites] Eur J Cancer Care (Engl). 2004 Sep;13(4):380-3 [15305907.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4410-7 [15514383.001]
  • [Cites] Oncology. 2005;68(4-6):326-32 [16020959.001]
  • [Cites] Oncology. 2005;69(1):63-70 [16088234.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Sep 1;30(5):452-8 [19549287.001]
  • [Cites] Cancer Res. 1980 Oct;40(10):3430-6 [7438030.001]
  • [Cites] Nihon Yakurigaku Zasshi. 1995 Jun;105(6):447-60 [7557733.001]
  • [Cites] Science. 1995 Jul 14;269(5221):230-4 [7618084.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):222-6 [7799023.001]
  • [Cites] Anticancer Drugs. 1993 Aug;4(4):443-5 [8400346.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):148-51 [8418225.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):329-38 [15558802.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):549-55 [16428499.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Support Oncol. 2006 Jun;4(6):289-94 [16805331.001]
  • [Cites] Oncologist. 2006 Sep;11(8):944-54 [16951398.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5491-5 [17000684.001]
  • [Cites] Support Care Cancer. 2007 May;15(5):483-90 [17103195.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jan;81(1):42-9 [17185998.001]
  • [Cites] Ther Drug Monit. 2007 Jun;29(3):265-70 [17529881.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):323-7 [17545794.001]
  • [Cites] Curr Oncol. 2007 Feb;14(1):13-20 [17576459.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3456-61 [17687149.001]
  • [Cites] J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5 [17728214.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1449-54 [17881902.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1028-34 [17895895.001]
  • [Cites] Oncology. 2007;72(1-2):10-6 [17998785.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):115-20 [18221820.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):49-52 [18253955.001]
  • [Cites] Cancer. 2008 May 1;112(9):1932-40 [18300238.001]
  • [Cites] J Nutr. 2008 Apr;138(4):740-6 [18356329.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Aug;5(8):455-65 [18542119.001]
  • [Cites] Br J Cancer. 2008 Jul 22;99(2):275-82 [18594531.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Curr Opin Support Palliat Care. 2008 Mar;2(1):19-21 [18685389.001]
  • (PMID = 21789126.001).
  • [ISSN] 1758-8359
  • [Journal-full-title] Therapeutic advances in medical oncology
  • [ISO-abbreviation] Ther Adv Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3126005
  • [Keywords] NOTNLM ; chemotherapy-induced diarrhea / frequency / irinotecan / loperamide / octreotide / pathophysiology / prevention management
  •  go-up   go-down


63. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L: Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol; 2005;22(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty patients with recurrent or metastatic advanced cancer, without bone metastases, were randomized into the trial to either receive zoledronic acid or no treatment.
  • [MeSH-major] Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Biochem. 2002 Jun;35(4):293-6 [12135691.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):846-54 [10071275.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):59-65 [8418243.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):10-7 [11134190.001]
  • [Cites] Bone. 1987;8 Suppl 1:S53-6 [2961355.001]
  • [Cites] Cancer Control. 1999 May;6(3):241-246 [10758553.001]
  • [Cites] Clin Chem. 1995 Nov;41(11):1560-6 [7586543.001]
  • [Cites] Semin Oncol. 2001 Jun;28(3):284-90 [11402438.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 21):33-42 [12584693.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):848-53 [12548585.001]
  • [Cites] Bone. 1996 Dec;19(6):663-7 [8968035.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):450-4 [8814691.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(2):263-9 [9741331.001]
  • [Cites] Cancer Treat Rev. 2003 Jun;29(3):189-98 [12787713.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4042-57 [12963702.001]
  • [Cites] Eur J Cancer Care (Engl). 1999 Dec;8(4):213-9 [10889618.001]
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S22-9 [14659140.001]
  • (PMID = 15965284.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


64. van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G, de Gruijl TD: Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol; 2007;2007:17315
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
  • Tumor-derived vascular endothelial growth factor (VEGF) has previously been identified as a causative factor in the disturbed differentiation of myeloid dendritic cells (DC) in advanced cancer patients.
  • To this end, peripheral blood DC (PBDC) precursor and subset frequencies were measured in 13 patients with advanced cancer before and after treatment with AZD2171, a TK inhibitor (TKI) of VEGFR, coadministered with gefitinib, and an epidermal growth factor receptor (EGFR) TKI.
  • Of note, not only myeloid DC but also plasmacytoid DC frequencies were significantly reduced in the blood of the cancer patients prior to treatment, as compared to healthy controls.
  • In conclusion, TK inhibition of VEGFR with AZD2171 does not restore the defective PBDC differentiation observed in advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Dec 15;100(13):4512-20 [12393628.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):636-45 [15634881.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1463-72 [14562018.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jun;53(6):543-50 [14666382.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1656-61 [15343347.001]
  • [Cites] Nat Med. 1996 Oct;2(10):1096-103 [8837607.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3245-87 [9345009.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):4772-80 [9366401.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):359-69 [9485215.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1224-32 [9570538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9349-54 [9689083.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):95-103 [9815891.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] Clin Immunol. 2006 Jun;119(3):317-29 [16527545.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9290-8 [16982774.001]
  • [Cites] Prostate. 2007 Jan 1;67(1):1-7 [17075798.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Immunol. 2000 Feb 1;164(3):1269-76 [10640740.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3045-54 [17634482.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1755-66 [10815894.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6037-46 [11086035.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3838-46 [11090068.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):678-89 [11123353.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4333-43 [11970975.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):483-90 [9815709.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4778-91 [9845545.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7260-9 [15534100.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):215-22 [15611243.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2138-45 [12750171.001]
  • (PMID = 18320010.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; NQU9IPY4K9 / cediranib; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2246026
  •  go-up   go-down


65. Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfinopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T, Pavlidis N, Hellenic Cooperative Oncology Group: Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol; 2008 Jun;66(3):237-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Cancer in the elderly is a common health issue in developed societies.
  • RESULTS: One thousand three hundred and seventy-two fit patients (PS 0-1 in 73%) with a median age of 70 years diagnosed with metastatic breast (n=250), colorectal (n=621) or lung cancer (n=501) received chemotherapy from 1991 until 2006.
  • At a median follow-up of 3 years, objective responses were seen in 41% of patients with breast cancer, 25% with colorectal cancer and 31% with lung cancer, while median survival was 21, 16 and 9.4 months, respectively.
  • In multivariate analysis, diagnosis of colorectal or lung cancer, metastases in multiple organ sites, presence of liver/brain/peritoneal deposits, impaired PS and low baseline serum albumin levels were prognostic factors for adverse outcome.
  • CONCLUSIONS: Our data indicate that relatively fit elderly patients with advanced cancer safely tolerate modern chemotherapy and enjoy disease control in a manner comparable to younger patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Comorbidity. Female. Humans. Male. Neoplasm Metastasis / drug therapy. Treatment Outcome


66. Zorzi M, Barca A, Falcini F, Grazzini G, Pizzuti R, Ravaioli A, Sassoli de Bianchi P, Senore C, Sigillito A, Vettorazzi M, Visioli C: Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev; 2007 Mar-Jun;31(2-3 Suppl 2):49-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for colorectal cancer in Italy: 2005 survey.
  • We present the main results from the second survey of the Italian screening programmes for colorectal cancer carried out by the National Centre for Screening Monitoring on behalf of the Ministry of Health.
  • At first screening, the detection rate (DR) per 1000 screened subjects was 3.7 and 16.8 for invasive cancer and advanced adenomas (AA) (adenomas with a diameter > or =1 cm, with villous/tubulo-villous type or with high-grade dysplasia) respectively; the corresponding figures at repeat screening were 1.1 for cancer and 4.9 for AA.
  • The DR of cancer and adenomas increased with age and it was higher among males, 55% of screen-detected cancers were at TNM stage I.
  • The positive predictive value (PPV) was 7.4% for cancer and 32.9% for AA at first screening, and 4.5% for cancer and 20.5% for AA at repeat screening.
  • Among subjects referred to colonoscopy the prevalence of proximal AA and cancer ranged from 5.4 to 11.1%.
  • The overall DR (subjects with at least one advanced lesion) ranged from 3.5 to 7.0%.
  • In conclusion, during 2005 the organised programmes for colorectal cancer screening in Italy increased considerably, covering about one third of the eligible population at a national level.


67. Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G: Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2006 Dec;17(12):1835-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: There is now increasing evidence that a constitutive expression of cyclooxygenase (COX)-2 plays a role in the development and progression of malignant epithelial tumors.
  • We designed a phase II study to assess the efficacy and toxicity of the combination of TMZ and celecoxib (a COX-2 inhibitor) in patients with advanced melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980601.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


68. Dunst CM, Swanström LL: Minimally invasive esophagectomy. J Gastrointest Surg; 2010 Feb;14 Suppl 1:S108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimally invasive approaches show most promise for benign disease and select early esophageal cancers, but their role in more advanced cancer remains controversial due to lack of long-term results.
  • CONCLUSION: As minimally invasive esophagectomy matures, its true value in both benign and malignant disorders will become better defined.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):40-5 [8447139.001]
  • [Cites] Ann Thorac Surg. 2003 Jan;75(1):217-22; discussion 222 [12537219.001]
  • [Cites] Br J Surg. 2008 May;95(5):602-10 [18324607.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1589-97 [17909921.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):486-94; discussion 494-5 [14530720.001]
  • [Cites] J Am Coll Surg. 2006 Aug;203(2):152-61 [16864027.001]
  • [Cites] Dis Esophagus. 2004;17(1):95-7 [15209750.001]
  • [Cites] J Am Coll Surg. 2006 Apr;202(4):588-96; discussion 596-8 [16571425.001]
  • [Cites] Surg Endosc. 2008 Apr;22(4):1060-9 [18071806.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):232-40 [17245176.001]
  • [Cites] Ann Surg. 2008 Aug;248(2):221-6 [18650631.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):376-84; discussion 384-5 [12192324.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):2070-5 [16305846.001]
  • [Cites] Surg Laparosc Endosc. 1995 Feb;5(1):1-5 [7735533.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):402-6; discussion 406-7 [16863737.001]
  • [Cites] J Med Assoc Thai. 2008 Aug;91(8):1202-5 [18788691.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):138-43 [1669393.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):42-50 [14698310.001]
  • [Cites] Dis Esophagus. 2008;21(3):220-5 [18430102.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):298-301 [16362469.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1062-6 [12917757.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1384-93; discussion 1393-4 [17764019.001]
  • [Cites] Surg Endosc. 2008 Nov;22(11):2485-91 [18320278.001]
  • [Cites] Surg Endosc. 1993 Nov-Dec;7(6):505-10 [8272996.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1395-402; discussion 1402 [17763917.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1308-9 [16897282.001]
  • [Cites] J Am Coll Surg. 2006 Jul;203(1):7-16 [16798482.001]
  • [Cites] Ann Thorac Surg. 1993 Sep;56(3):675-9 [8379769.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):7-11 [1573620.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Oct;6(9):818-49 [18926093.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):665-71; discussion 671-4 [17893503.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):22-8 [17185194.001]
  • [Cites] J Am Coll Surg. 2003 Dec;197(6):902-13 [14644277.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4 [17717440.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 Jan;35(1):13-20; discussion 20-1 [18952454.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):522-6 [12127116.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):324-35; discussion 335-6 [12192319.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):549-56 [18936567.001]
  • [Cites] Arch Surg. 1997 Sep;132(9):943-7; discussion 947-9 [9301605.001]
  • (PMID = 19789930.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Mirhosseini M, Oneschuk D, Hunter B, Hanson J, Quan H, Amigo P: The role of antibiotics in the management of infection-related symptoms in advanced cancer patients. J Palliat Care; 2006;22(2):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of antibiotics in the management of infection-related symptoms in advanced cancer patients.
  • We prospectively evaluated the effect of antibiotic treatment on infection-related symptoms in patients with advanced cancer, in addition to assessing infection characteristics.
  • Further comparative studies to evaluate symptomatic benefit, patient burden, and cost/benefit of antibiotic therapy in the treatment of infections in advanced cancer patients are required.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265658.001).
  • [ISSN] 0825-8597
  • [Journal-full-title] Journal of palliative care
  • [ISO-abbreviation] J Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


70. Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C: A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Invest New Drugs; 2006 Jul;24(4):327-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
  • We conducted a phase I study to define the toxicity, pharmacokinetics and antitumor activity of CS-682 in patients with advanced solid tumors.
  • The most common tumor type was colorectal cancer with 15 patients.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):226-36 [10389757.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):725-31 [11259616.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4417-22 [2364394.001]
  • (PMID = 16502355.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / sapacitabine; 8J337D1HZY / Cytosine
  •  go-up   go-down


71. Dy SM, Apostol CC: Evidence-based approaches to other symptoms in advanced cancer. Cancer J; 2010 Sep-Oct;16(5):507-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based approaches to other symptoms in advanced cancer.
  • Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer.
  • The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction.
  • For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890148.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


72. Giordano G, Gnetti L, Merisio C, Melpignano M: Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps. Maturitas; 2007 Feb 20;56(2):190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
  • OBJECTIVES: We analyzed clinical data and pathological features of six cases of malignant endometrial polyps, to compare these with other examples reported in literature and to define the features of endometrial cancer arising in polyps.
  • Moreover, to clarify the mechanisms of carcinogenesis in malignant endometrial polyps we examined the expression of cyclooxygenase-2 (COX-2), P53 and Ki 67 and their relationships with clinicopathologic characteristics.
  • The main pathological features analyzed were histological types of endometrial cancer and the stage of development of neoplasm.
  • RESULTS: In our study, all malignant endometrial polyps had been detected in postmenopausal women.
  • The majority of our patients with malignant endometrial polyps had risk factors for the development of endometrial carcinoma such as hypertension, obesity and unopposed estrogen therapy.
  • The most common subtypes of endometrial carcinoma in malignant polyps are endometrioid carcinoma and serous papillary carcinoma.
  • P53 and Ki 67 expression, detected in the nuclei of neoplastic cells, was not correlated with COX-2 immunoreactivity, but these markers were associated with more advanced stage, grading, and histologic subtypes of tumor.
  • P53 and Ki 67 overexpression, instead, are associated with advanced stage, histologic subtype and deep myometrial invasion of neoplasm.


73. Seper L, Schwab R, Kiattavorncharoen S, Büchter A, Bánkfalvi A, Joos U, Piffkó J, Kruse-Loesler B: Malignant fibrous histiocytoma of the face: report of a case. Head Face Med; 2007;3:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the face: report of a case.
  • Excision biopsy of the recurrent lesion revealed a malignant fibrous histiocytoma (MFH).
  • DISCUSSION: Malignant transformation of BFH is extremely rare and if so, extended radical surgery may give a fair chance for a favourable outcome even in patients with advanced age.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / surgery. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neck Dissection / methods. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):668-76 [8017561.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • (PMID = 17945018.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211745
  •  go-up   go-down


74. Droney J, Nam bisan V, Jennings AL, Riley J: Spinal myoclonus in advanced cancer. J Pain Symptom Manage; 2008 Oct;36(4):e3-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal myoclonus in advanced cancer.

  • Genetic Alliance. consumer health - Myoclonus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922378.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


75. Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL, Barbosa-Morais NL, Mukherjee G, Thorne NP, Roberts I, Pett MR, Coleman N: Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol; 2007 Aug;212(4):368-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gain of chromosome 5p is seen in over 50% of advanced cervical squamous cell carcinomas (SCCs), although the genes responsible for the selective advantage provided by this abnormality are poorly understood.
  • Drosha copy-number and expression were not elevated in pre-malignant cervical squamous intraepithelial lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. MicroRNAs / genetics. RNA, Neoplasm / genetics. Ribonuclease III / metabolism. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Cells, Cultured. Chromosomes, Human, Pair 5 / genetics. Female. Humans. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Polymerase Chain Reaction / methods. Principal Component Analysis


76. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S: Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol; 2009 Jul 15;183(2):937-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Individuals with advanced cancer are immune suppressed due to myeloid-derived suppressor cells (MDSC), a population of immature myeloid cells that accumulate to high levels in response to tumor-secreted and proinflammatory factors.
  • We now demonstrate that the reduction in T cell levels of L-selectin that is commonly seen in individuals with cancer inversely correlates with MDSC levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2009 May 7;113(19):4729-39 [19196663.001]
  • [Cites] Cancer Immunol Immunother. 2000 Apr;49(1):34-45 [10782864.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2710-5 [10825145.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):779-85 [10878351.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5738-49 [11067932.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):678-89 [11123353.001]
  • [Cites] J Leukoc Biol. 2000 Dec;68(6):865-72 [11129654.001]
  • [Cites] J Exp Med. 2001 Apr 2;193(7):863-72 [11283159.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5398-406 [11313376.001]
  • [Cites] J Immunother. 2001 Nov-Dec;24(6):431-46 [11759067.001]
  • [Cites] Mech Ageing Dev. 2007 Nov-Dec;128(11-12):672-80 [18036633.001]
  • [Cites] Cancer Immunol Immunother. 2002 Aug;51(6):293-8 [12111117.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):563-9 [12504120.001]
  • [Cites] Trends Immunol. 2003 Jun;24(6):302-6 [12810105.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):630-41 [12974478.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1323-35 [14597735.001]
  • [Cites] Inflammation. 2003 Oct;27(5):265-80 [14635784.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):64-72 [14593498.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):989-99 [14707072.001]
  • [Cites] Annu Rev Immunol. 2004;22:129-56 [15032576.001]
  • [Cites] Nature. 1983 Jul 7-13;304(5921):30-4 [6866086.001]
  • [Cites] J Immunol. 1988 Dec 15;141(12):4110-7 [3058798.001]
  • [Cites] Science. 1989 Sep 15;245(4923):1238-41 [2551036.001]
  • [Cites] J Immunol. 1990 Apr 15;144(8):3130-6 [2182714.001]
  • [Cites] Eur J Immunol. 1992 May;22(5):1279-86 [1374339.001]
  • [Cites] J Immunol. 1993 Dec 15;151(12):6777-82 [7505015.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):25-34 [8006585.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2401-6 [7525854.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3106-12 [7528669.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):669-75 [7530761.001]
  • [Cites] Immunity. 1994 Jul;1(4):247-60 [7534203.001]
  • [Cites] J Exp Med. 1995 Jun 1;181(6):2259-64 [7539045.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):589-98 [8627170.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):847-51 [8631602.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11376-82 [8626692.001]
  • [Cites] Scand J Immunol. 1996 Jul;44(1):37-44 [8693290.001]
  • [Cites] Lab Invest. 1996 Jul;75(1):67-76 [8683941.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):978-83 [8757600.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5653-9 [8955218.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5191-9 [9164936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91 [9192661.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1486-93 [9537252.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1281-4 [9812885.001]
  • [Cites] J Biol Chem. 1999 Jan 29;274(5):2810-5 [9915814.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):22072-80 [10419535.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):2176-86 [10438959.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):636-45 [15634881.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):255-66 [15963248.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6713-21 [16166452.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):931-9 [16186186.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):8200-8 [16339559.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11639-48 [16357175.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11743-51 [16357187.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):284-90 [16365420.001]
  • [Cites] Clin Exp Immunol. 2006 Feb;143(2):216-27 [16412045.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Aug;30(2):362-9 [16828564.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2275-9 [16735599.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):425; author reply 426 [17210725.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4812-20 [17172469.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):977-83 [17617589.001]
  • [Cites] Nat Med. 2007 Jul;13(7):828-35 [17603493.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):678-89 [17717539.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):10019-26 [17942936.001]
  • [Cites] J Biol Chem. 2007 Nov 16;282(46):33714-24 [17884817.001]
  • [Cites] Cell Res. 2007 Dec;17(12):985-98 [18040288.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2427-35 [18381451.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):3-10 [18325755.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3291-300 [18714001.001]
  • [Cites] J Immunol. 2008 Oct 1;181(7):4666-75 [18802069.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2235-49 [18809714.001]
  • [Cites] Infect Immun. 2008 Nov;76(11):5191-9 [18765736.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2449-57 [19201900.001]
  • (PMID = 19553533.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA119768; United States / NCI NIH HHS / CA / R01 CA115880; United States / NCI NIH HHS / CA / R01CA115880; United States / NCI NIH HHS / CA / 5F32CA119768-03; United States / NCI NIH HHS / CA / R01 CA084232; United States / NCI NIH HHS / CA / R01 CA084232-07; United States / NCI NIH HHS / CA / R01CA84232; United States / NCI NIH HHS / CA / CA115880-04; United States / NCI NIH HHS / CA / CA084232-07; United States / NCI NIH HHS / CA / R01 CA115880-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 126880-86-2 / L-Selectin; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  • [Other-IDs] NLM/ NIHMS163050; NLM/ PMC2800824
  •  go-up   go-down


77. Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T: Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer; 2009 Dec;17(12):1469-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients affected with advanced cancer were treated with palonosetron 250 mcg plus dexamethasone 20 mg before HEC.

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Oct;14(10):1570-7 [14504060.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):20-8 [16314401.001]
  • [Cites] Ther Clin Risk Manag. 2007 Dec;3(6):1009-20 [18516316.001]
  • [Cites] Eur J Oncol Nurs. 2005;9 Suppl 2:S51-63 [16437758.001]
  • [Cites] Clin Nutr. 2007 Jun;26(3):289-301 [17368656.001]
  • [Cites] Expert Opin Pharmacother. 2003 Dec;4(12):2297-303 [14640928.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2473-82 [14635083.001]
  • [Cites] Ann Oncol. 2006 Sep;17(9):1441-9 [16766588.001]
  • [Cites] Anesth Analg. 2008 Aug;107(2):469-78 [18633025.001]
  • [Cites] Support Care Cancer. 2009 Mar;17(3):279-84 [18581148.001]
  • (PMID = 19294429.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Antineoplastic Agents; 0 / Isoquinolines; 0 / Quinuclidines; 0 / Serotonin Antagonists; 5D06587D6R / palonosetron; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


78. Fadul N, Elsayem A, Palmer JL, Zhang T, Braiteh F, Bruera E: Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med; 2007 Oct;10(5):1146-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center.
  • PURPOSE: Palliative care services can decrease physical and psychosocial distress in patients with advanced cancer.
  • However, most patients with cancer die without access to palliative care services (APCS), and patterns of referral are not well understood.
  • Anderson Cancer Center over 2 (2003 and 2004) to determine differences in characteristics and outcomes between patients with and without APCS.
  • RESULTS: A total of 499 of 1453 (34%) inpatients who died at our cancer center had APCS.
  • Mortality in comprehensive cancer centers is quite variable among different primary malignancies.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985971.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Zhang X, Ling MT, Wang X, Wong YC: Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer; 2006 Apr 15;118(8):2072-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.
  • Resistance to anticancer drugs is the major problem in the treatment of many advanced cancers, including androgen-independent prostate cancer.
  • Recently, increased expression of Id-1, a basic helix-loop-helix protein, is reported in several types of advanced cancer.
  • It is suggested that high expression of Id-1 may provide an advantage for cancer cell survival and inactivation of Id-1 may be able to increase cancer cells' susceptibility to apoptosis.
  • To test this hypothesis, in this study, by using RNA interfering technology, we inactivated the Id-1 gene in 2 androgen-independent prostate cancer cell lines, DU145 and PC3, and investigated whether downregulation of Id-1 could lead to increased sensitivity to a commonly used anticancer drug, taxol.
  • By using colony forming assay and MTT assay, we found that inactivation of Id-1 resulted in both decreased colony forming ability and cell viability in prostate cancer cells, after taxol treatment.
  • These results indicate that increased Id-1 expression in prostate cancer cells may play a protective role against apoptosis, and downregulation of Id-1 may be a potential target to increase sensitivity of taxol-induced apoptosis in prostate cancer cells.
  • [MeSH-minor] Apoptosis. Cell Survival. Down-Regulation. Drug Resistance, Neoplasm. Enzyme Activation. Gene Expression Profiling. Humans. Male. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287090.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Inhibitor of Differentiation Protein 1; EC 2.7.12.2 / MAP Kinase Kinase 4; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


81. Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT: A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg; 2009 Dec;250(6):957-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
  • SUMMARY BACKGROUND DATA: FDG-PET/CT imaging is increasingly used for staging of pancreatic cancer.
  • In the differential diagnosis of suspected malignant biliary stricture at endoscopic retrograde cholangiopancreaticography (n = 21), FDG-PET/CT had a positive predictive value of 92%.
  • In 17 patients with advanced pancreatic adenocarcinoma, FDG-PET/CT had a sensitivity of 30% for N- and 88% for M-staging.
  • [MeSH-major] Cholangiopancreatography, Magnetic Resonance / methods. Fluorodeoxyglucose F18. Neoplasm Staging / methods. Pancreatic Neoplasms / diagnosis. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687736.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Ryan PY: Approaching death: a phenomenologic study of five older adults with advanced cancer. Oncol Nurs Forum; 2005 Nov;32(6):1101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Approaching death: a phenomenologic study of five older adults with advanced cancer.
  • PURPOSE/OBJECTIVES: To explore the lived experience and the associated meaning of approaching death among older adults with advanced cancer.
  • SETTING: Urban cancer center.
  • PARTICIPANTS: 5 individuals diagnosed with advanced cancer who were 65 years or older.
  • FINDINGS: The study elucidated the experience of approaching death from advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270106.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Belting M, Ahamed J, Ruf W: Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol; 2005 Aug;25(8):1545-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling of the tissue factor coagulation pathway in angiogenesis and cancer.
  • Advanced cancer is associated with a hypercoagulable state, and tissue factor expression by cancer cells has received widespread attention because of its significant contribution to the pathogenesis of cancer progression and metastasis.
  • Our recent work demonstrates that tissue factor-mediated cellular signaling is relevant to cancer angiogenesis.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905465.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9035-58-9 / Thromboplastin
  • [Number-of-references] 51
  •  go-up   go-down


84. Medioni J, Dionysopoulos D, Banu E, Scotté F, Beuzeboc P, Oudard S: [Chemotherapy for prostate cancer]. Presse Med; 2008 May;37(5 Pt 2):814-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for prostate cancer].
  • [Transliterated title] Chimiothérapie du cancer de la prostate.
  • Chemotherapy treatment for patients with prostate cancer has advanced considerably during the past decade.
  • The first demonstration of the efficacy of palliative chemotherapy in patients with hormone-resistant prostate cancer was followed by FDA approval of mitoxantrone in this setting and by studies showing the usefulness of several different drugs in these patients.
  • The development of new cytotoxic molecules and targeted therapies as well as the evaluation of the efficacy of docetaxel in earlier stages of prostate cancer, with many ongoing studies, are the current lines of research for improving management of these hormone-refractory patients.
  • [MeSH-minor] Calcitriol / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Drug Resistance, Neoplasm. Estramustine / therapeutic use. Humans. Male. Neoadjuvant Therapy. Taxoids / pharmacology. Taxoids / therapeutic use. Vitamins / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160251.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 0 / Vitamins; 15H5577CQD / docetaxel; 35LT29625A / Estramustine; FXC9231JVH / Calcitriol
  • [Number-of-references] 30
  •  go-up   go-down


85. Sundar SS, Gornall RJ, Kehoe ST: Advances in the management of cervical cancer. J Br Menopause Soc; 2005 Sep;11(3):91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of cervical cancer.
  • This review presents key advances in the management of cervical cancer.
  • Traditionally, cervical cancer is staged clinically and has been treated either by radical hysterectomy or by radiotherapy.
  • The evidence on fertility-preserving surgery for cervical cancer and chemoradiotherapy for locally advanced cancer is summarized here.
  • An improved understanding of the viral aetiology of cervical cancer has led to the development of therapeutic vaccination, with limited success.
  • There is increasing recognition of the psychosexual needs of women who have survived cervical cancer.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Staging. Papillomaviridae / immunology. Viral Vaccines


86. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the total, 5.3% were papillary urothelial tumours of low malignant potential, 33.3% pTa, 20% pT1, 10.7% pT2, 12.0% pT3 and 18.7% pT4.
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • Mean survival of patients with muscle invasive cancer was 33+/-5 months.
  • By the end of the study, 18.1% of patients had died of their cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Malaysia. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


87. Kim J, Jang KT, Kim KH, Park JW, Chang BJ, Lee KH, Lee JK, Heo JS, Choi SH, Choi DW, Rhee JC, Lee KT: Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer. Tumour Biol; 2010 Oct;31(5):471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer.
  • Mammary serine protease inhibitor (maspin, SERPIN-B5) is expressed in normal human mammary epithelial cells and is known to be down-regulated during cancer progression.
  • Aberrant maspin expression has been reported in a number of cancers, including pancreatic and ovarian cancer.
  • Recently, we identified several genes that may be tumor markers for gallbladder (GB) cancer using a DNA microarray method.
  • There are no published data regarding maspin expression in GB cancer.
  • The aims of this study were to determine maspin expression in normal mucosa, adenoma, dysplasia and carcinoma of GB, and to compare the pattern of maspin expression in early and advanced GB cancers.
  • One hundred one patients with primary GB cancer who underwent resection between March 1999 and May 2008 were included.
  • The positive rate of maspin expression was 59.4% (60/101) in GB cancer, whereas no maspin was expressed in adenomas and normal mucosa of GB.
  • No significant difference in the positive rate of maspin expression between early and advanced cancer was detected (49% versus 60%; P = 0.731).
  • [MeSH-minor] Adenoma / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):499-504 [9435220.001]
  • [Cites] Science. 1994 Jan 28;263(5146):526-9 [8290962.001]
  • [Cites] Tumour Biol. 2008;29(1):41-9 [18497548.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):651-60 [16329135.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2924-32 [12231537.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):812-7 [11309327.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):214-24 [15608662.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):51-64 [8814994.001]
  • [Cites] Acta Oncol. 2000;39(8):931-4 [11206999.001]
  • [Cites] Mod Pathol. 2007 May;20(5):570-8 [17396143.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):328-30 [16505288.001]
  • [Cites] Oncogene. 2000 May 11;19(20):2398-403 [10828881.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):615-23 [16724345.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7279-83 [17189399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11669-74 [8876194.001]
  • [Cites] J Biol Chem. 1994 Dec 9;269(49):30988-93 [7983035.001]
  • [Cites] Dig Dis Sci. 2002 Aug;47(8):1831-5 [12184537.001]
  • (PMID = 20517662.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


88. Reyes-Ortiz CA, Eschbach K, Zhang DD, Goodwin JS: Neighborhood composition and cancer among Hispanics: tumor stage and size at time of diagnosis. Cancer Epidemiol Biomarkers Prev; 2008 Nov;17(11):2931-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neighborhood composition and cancer among Hispanics: tumor stage and size at time of diagnosis.
  • BACKGROUND: We have previously reported that cancer incidence for lung, female breast, and colon and rectum for Hispanics decreases with increasing percentage of Hispanics at the census tract.
  • In contrast, cervical cancer incidence increases with increasing percentage of Hispanics at the census tract.
  • METHODS: In this study, we investigate the hypothesis that Hispanics living in census tracts with high percentages of Hispanics are diagnosed with more advanced cancer, with respect to tumor size and stage of diagnosis.
  • Census Bureau were used to estimate the odds of diagnosis at a "late" stage (II, III, IV) versus "early" stage (I) and breast cancer tumor size among Hispanics as a function of census tract percent Hispanic.
  • RESULTS: We found that Hispanics living in neighborhoods with higher density of Hispanic populations were more likely to be diagnosed with late-stage breast, cervical, or colorectal cancer, and to have a larger tumor size of breast cancer.
  • CONCLUSIONS: Our findings suggest that the benefits of lower cancer incidence in high tract percent Hispanics are partially offset by poorer access and reduced use of screening in conjunction with lower income, poorer health insurance coverage, and language barriers typical of these communities.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Jun;29(3):470-7 [10869319.001]
  • [Cites] Ann Epidemiol. 2008 Jan;18(1):43-7 [17890103.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):363-71 [11207154.001]
  • [Cites] Soc Sci Med. 2001 Jul;53(1):41-53 [11386307.001]
  • [Cites] Am J Public Health. 2001 Sep;91(9):1424-30 [11527775.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110 Suppl 2:195-201 [11929728.001]
  • [Cites] Hum Biol. 2002 Feb;74(1):83-109 [11931581.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):218-28 [11979437.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):229-37 [11979438.001]
  • [Cites] Public Health Rep. 2001 Sep-Oct;116(5):404-16 [12042604.001]
  • [Cites] Am J Public Health. 2003 Feb;93(2):200-8 [12554570.001]
  • [Cites] Soc Sci Med. 2003 Dec;57(11):2023-34 [14512234.001]
  • [Cites] Health Serv Res. 2003 Dec;38(6 Pt 2):1719-33 [14727794.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1051-7 [15329915.001]
  • [Cites] Public Health Rep. 1986 May-Jun;101(3):253-65 [3086917.001]
  • [Cites] J Natl Cancer Inst. 1987 Sep;79(3):457-63 [3476788.001]
  • [Cites] J Natl Cancer Inst. 1988 May 18;80(6):432-8 [3367383.001]
  • [Cites] Demography. 1989 Aug;26(3):373-91 [2792476.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] JAMA. 1993 Nov 24;270(20):2464-8 [8031341.001]
  • [Cites] Am J Public Health. 1995 Jan;85(1):20-5 [7832256.001]
  • [Cites] J Natl Cancer Inst Monogr. 1995;(18):17-28 [8562218.001]
  • [Cites] J Natl Cancer Inst Monogr. 1995;(18):35-9 [8562220.001]
  • [Cites] J Natl Cancer Inst Monogr. 1995;(18):73-82 [8562225.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):761-71 [9081351.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1031-8 [8683633.001]
  • [Cites] Am J Public Health. 1990 Dec;80 Suppl:20-6 [9187577.001]
  • [Cites] Am J Public Health. 1990 Dec;80 Suppl:42-6 [9187581.001]
  • [Cites] Cancer. 1998 May 1;82(9):1769-83 [9576301.001]
  • [Cites] Am J Epidemiol. 1999 Jun 1;149(11):1063-71 [10355383.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):1036-44 [15672387.001]
  • [Cites] Annu Rev Public Health. 2005;26:367-97 [15760294.001]
  • [Cites] Am J Public Health. 2005 Apr;95(4):660-7 [15798127.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 Feb;60(2):207-12 [15814864.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2005 Oct;60 Spec No 2:68-75 [16251594.001]
  • [Cites] Epidemiology. 2006 Jan;17(1):14-23 [16357590.001]
  • [Cites] J Epidemiol Community Health. 2006 Mar;60(3):202-7 [16476748.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2006 Jul;61(4):S203-11 [16855041.001]
  • [Cites] Int J Epidemiol. 2006 Aug;35(4):903-19 [16709619.001]
  • [Cites] Ann Intern Med. 2007 Apr 3;146(7):493-501 [17404351.001]
  • [Cites] J Epidemiol Community Health. 2007 May;61(5):409-15 [17435207.001]
  • [Cites] Soc Sci Med. 2007 Aug;65(4):809-21 [17499411.001]
  • [Cites] J Natl Cancer Inst. 2007 Sep 19;99(18):1384-94 [17848670.001]
  • [Cites] Am J Prev Med. 2007 Nov;33(5):379-386 [17950403.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):901-12 [10951356.001]
  • (PMID = 18990733.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K05 CA134923; United States / NCI NIH HHS / CA / P50 CA105631; United States / NCI NIH HHS / CA / P50 CA10563-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS507962; NLM/ PMC3763513
  •  go-up   go-down


89. Fainsinger RL, Nekolaichuk CL: A "TNM" classification system for cancer pain: the Edmonton Classification System for Cancer Pain (ECS-CP). Support Care Cancer; 2008 Jun;16(6):547-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "TNM" classification system for cancer pain: the Edmonton Classification System for Cancer Pain (ECS-CP).
  • OBJECTIVE: The purpose of this paper is to provide an overview of the development of a "TNM" cancer pain classification system for advanced cancer patients, the Edmonton Classification System for Cancer Pain (ECS-CP).
  • Until we have a common international language to discuss cancer pain, understanding differences in clinical and research experience in opioid rotation and use remains problematic.
  • The complexity of the cancer pain experience presents unique challenges for the classification of pain.
  • To date, no universally accepted pain classification measure can accurately predict the complexity of pain management, particularly for patients with cancer pain that is difficult to treat.
  • MATERIALS AND METHODS: In response to this gap in clinical assessment, the Edmonton Staging System (ESS), a classification system for cancer pain, was developed.
  • CONCLUSION: The development of a standardized classification system that is comprehensive, prognostic and simple to use could provide a common language for clinical management and research of cancer pain.

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 1995 Jul;10(5):348-55 [7673767.001]
  • [Cites] Can Med Assoc J. 1971 Oct 23;105(8):836 passim [5162408.001]
  • [Cites] Pain. 1988 Apr;33(1):11-23 [2454440.001]
  • [Cites] Pain. 1999 Sep;82(3):263-74 [10488677.001]
  • [Cites] J Pain Symptom Manage. 1999 Nov;18(5):347-52 [10584458.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Feb;10(1):57-78 [8821560.001]
  • [Cites] Acta Anaesthesiol Scand Suppl. 1998;113:24-8 [9932116.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Feb;256(2):575-80 [1847202.001]
  • [Cites] Support Care Cancer. 2000 Mar;8(2):123-30 [10739359.001]
  • [Cites] Am J Hosp Pharm. 1994 Jul 1;51(13):1643-56 [7942889.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):850-6 [3802043.001]
  • [Cites] N Engl J Med. 1996 Oct 10;335(15):1124-32 [8813044.001]
  • [Cites] Lancet. 1992 Jun 6;339(8806):1367-71 [1350803.001]
  • [Cites] Pain. 2003 Jan;101(1-2):55-64 [12507700.001]
  • [Cites] Oncology (Williston Park). 1998 Apr;12(4):517-21, 524 [9575525.001]
  • [Cites] Pain. 1990 Dec;43(3):273-86 [1705692.001]
  • [Cites] Med Clin North Am. 1982 Sep;66(5):1079-89 [7132470.001]
  • [Cites] Palliat Med. 1998 Nov;12(6):463-4 [10621867.001]
  • [Cites] Palliat Med. 2005 Sep;19(6):466-76 [16218159.001]
  • [Cites] Pain. 1995 Oct;63(1):65-76 [8577492.001]
  • [Cites] J Pain Symptom Manage. 2000 Mar;19(3):229-34 [10760628.001]
  • [Cites] J Pain Symptom Manage. 2008 Jan;35(1):51-7 [17980551.001]
  • [Cites] Pain. 1999 May;81(1-2):129-34 [10353500.001]
  • [Cites] J Pain Symptom Manage. 1995 Jul;10(5):378-84 [7673770.001]
  • [Cites] J Pain Symptom Manage. 1995 Nov;10(8):632-8 [8594124.001]
  • [Cites] Pain. 1989 May;37(2):203-9 [2748193.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1695-700 [10335806.001]
  • [Cites] Pain. 1995 Aug;62(2):141-6 [8545138.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1713-7 [8622092.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):834-42 [8608472.001]
  • [Cites] J Pain Symptom Manage. 1997 Jun;13(6):356-61 [9204657.001]
  • [Cites] J Pain Symptom Manage. 2005 Mar;29(3):224-37 [15781173.001]
  • [Cites] J Pain Symptom Manage. 2002 Nov;24(5):526-42 [12547052.001]
  • [Cites] Pain. 2002 Sep;99(1-2):5-10 [12237179.001]
  • [Cites] J Pain Symptom Manage. 1997 Jun;13(6):319-26 [9204651.001]
  • [Cites] Cancer Pract. 2002 May-Jun;10 Suppl 1:S58-65 [12027971.001]
  • [Cites] J Pain Symptom Manage. 2002 Oct;24(4):366-78 [12505205.001]
  • [Cites] J Pain Symptom Manage. 1995 Nov;10(8):599-603 [8594120.001]
  • [Cites] Pain. 1999 Aug;Suppl 6:S141-7 [10491983.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1520-7 [7751901.001]
  • (PMID = 18320239.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


90. Weber C, Merminod T, Herrmann FR, Zulian GB: Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer; 2008 Jul;16(7):847-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study.
  • GOALS: The objective of this study was to determine utility of prophylactic anti-coagulation in cancer patients hospitalised for palliative care in a specialised centre.
  • Twenty patients aged 55 to 88 years with advanced cancer and an estimated life expectancy of less than 6 months were assigned to either receive treatment with 2,850/3,800 U (<70/>70 kg) of daily subcutaneous nadroparin or no treatment.
  • CONCLUSIONS: Decision to administer prophylactic nadroparin in hospitalised cancer patients under palliative care remains a challenge.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 2000 Aug;20(2):130-9 [10989251.001]
  • [Cites] CMAJ. 1998 Jun 30;158(13):1717-26 [9676549.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):286-94 [1988575.001]
  • [Cites] Thromb Res. 2003 Jun 1;110(4):167-72 [14512077.001]
  • [Cites] Palliat Med. 1997 Nov;11(6):462-8 [9519169.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1264-8 [6547874.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] Cancer J. 2005 Nov-Dec;11(6):437-41 [16393477.001]
  • [Cites] Palliat Med. 2001 May;15(3):261-4 [11407200.001]
  • [Cites] BMJ. 2003 Jan 11;326(7380):93-6 [12521976.001]
  • [Cites] Clin Radiol. 1987 Jan;38(1):95-6 [3816073.001]
  • [Cites] N Engl J Med. 1999 Sep 9;341(11):793-800 [10477777.001]
  • [Cites] J Am Geriatr Soc. 2003 Oct;51(10):1472-8 [14511171.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Ann Biol Clin (Paris). 2000 Nov-Dec;58(6):675-82 [11098164.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2219-26 [14676798.001]
  • [Cites] J Pain Symptom Manage. 1992 May;7(4):192-5 [1517640.001]
  • [Cites] Circulation. 2004 Aug 17;110(7):874-9 [15289368.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):225-6 [15191013.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):439-49 [15274057.001]
  • [Cites] Lancet. 1998 Apr 11;351(9109):1077-80 [9660575.001]
  • [Cites] J Palliat Med. 2002 Oct;5(5):729-37 [12572972.001]
  • [Cites] Adv Clin Rehabil. 1987;1:6-18 [3503663.001]
  • (PMID = 17940809.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Nadroparin
  •  go-up   go-down


91. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z: Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother; 2005 Jul-Aug;39(7-8):1194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We identified 4 men and 3 women between the ages of 52 and 70 years, with multiple myeloma or different types of metastatic cancer, who had experienced renal impairment during zoledronic acid therapy.
  • Our data confirm the previously reported risk factors for zoledronic acid-associated nephrotoxicity such as advanced cancer, multiple myeloma, preexisting renal failure, diabetes, hypertension, and concomitant use of nephrotoxic drugs.

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956222.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


92. Sugarbaker DJ, Wolf AS: Surgery for malignant pleural mesothelioma. Expert Rev Respir Med; 2010 Jun;4(3):363-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for malignant pleural mesothelioma.
  • The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy.
  • The former is indicated for patients with advanced locally invasive disease; the latter for patients with more superficial spread of tumor that spares the lung and fissures.
  • Despite having more advanced disease, a subset of patients with favorable prognostic factors can experience extended survival by undergoing trimodality therapy with extrapleural pneumonectomy, chemotherapy and/or radiation.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Thoracotomy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524919.001).
  • [ISSN] 1747-6356
  • [Journal-full-title] Expert review of respiratory medicine
  • [ISO-abbreviation] Expert Rev Respir Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


93. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol; 2010 Jun 10;28(17):2839-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
  • Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy.
  • To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer.
  • PATIENTS AND METHODS: This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


94. Hiçsönmez A, Köse K, Andrieu MN, Güney Y, Kurtman C: The European Organization for Research and Treatment of Cancer core quality of life questionnaire (QLQ-C30 version 3.0 Turkish) in cancer patients receiving palliative radiotherapy. Eur J Cancer Care (Engl); 2007 May;16(3):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European Organization for Research and Treatment of Cancer core quality of life questionnaire (QLQ-C30 version 3.0 Turkish) in cancer patients receiving palliative radiotherapy.
  • The aim of this study was to evaluate the efficacy of palliative radiotherapy in patients with advanced cancer in terms of improvement in the quality of life [quality of life questionnaire (QLQ)], and to assess the correlation between the Eastern Cooperative Oncology Group (ECOG) performance status and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 (Turkish version 3.0).
  • A total of 88 patients with advanced malignant disease treated with palliative radiotherapy were included in the study.
  • Most patients (87.5%) had metastatic disease, and the remaining (12.5%) had locally advanced disease.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508945.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Thomas T, Abrams KA, Robinson RJ, Mayberry JF: Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther; 2007 Mar 15;25(6):657-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis.
  • BACKGROUND: The cancer risk of low-grade dysplasia (LGD) in chronic ulcerative colitis is variable and its management remain contentious.
  • AIM: To determine the risk of cancer or any advanced lesion once LGD is diagnosed.
  • METHODS: A MEDLINE, EMBASE and Pub Med search was conducted using the key words 'surveillance', 'colorectal cancer', 'low-grade dysplasia' and 'ulcerative colitis'.
  • An average of 18 biopsies taken per colonoscopy (range: 9-24) detected 73 advanced lesions (cancer or high-grade dysplasia) pre-operatively.
  • The cancer incidence was 14 of 1000 (95% CI: 5.0-34) person years duration (pyd) and the incidence of any advanced lesion was 30 of 1000 pyd (95% CI: 12-76).
  • When LGD is detected on surveillance there is a ninefold risk of developing cancer (OR: 9.0, 95% CI: 4.0-20.5) and 12-fold risk of developing any advanced lesion (OR: 11.9, 95% CI: 5.2-27).
  • CONCLUSIONS: The risk of developing cancer in patients with LGD is high.

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311598.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


96. Swanson G, Thompson I, Basler J, Crawford ED: Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol; 2006 Oct;176(4 Pt 1):1292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate cancer-does treatment of the primary tumor matter?
  • PURPOSE: In recent years there has been increased interest in adjuvant therapy for prostate cancer.
  • This trend has engendered a tendency toward overlooking the issue of therapy to the primary tumor in advanced disease.
  • We reviewed the effect of treating the principal disease bulk on overall treatment outcome in patients with advanced and metastatic cancer.
  • MATERIALS AND METHODS: We performed a comprehensive literature review to evaluate the role of surgical debulking on the outcome of advanced cancer, including any published evidence supporting a benefit of this therapy for prostate cancer.
  • The beneficial role of maximal surgical cytoreduction has been clearly demonstrated in advanced ovarian cancer and gastrointestinal carcinomatosis.
  • Removal of the primary tumor has been proved to increase survival in randomized trials of metastatic renal cell cancer.
  • It appears that patients with node positive and possibly metastatic prostate cancer have a better response to androgen ablation with surgical removal of the gland.
  • CONCLUSIONS: Surgical cytoreduction of cancer results in a more favorable and durable response to systemic therapy.
  • It is reasonable to explore aggressive surgical therapy for advanced prostate cancer.
  • [MeSH-major] Neoplasm Metastasis / prevention & control. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging. Survival Rate


97. Yang CH, Chen MC, Cheng AL, Hsu CH, Yeh KH, Yu YC, Whang-Peng J, Yang PC: Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment. Oncology; 2005;68(4-6):350-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
  • OBJECTIVE: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC).
  • Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 S. Karger AG, Basel.
  • (PMID = 16020962.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


98. Ren Y, Ma L, Tian J, Zhang L, Yang K: [A systematic review on different treatment methods of bone metastasis from cancers]. Zhongguo Fei Ai Za Zhi; 2010 May;13(5):533-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: Skeletal metastase is one of the most common complications related to advanced cancer.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677655.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 30
  •  go-up   go-down


99. Nieminen A, Kokkola A, Ylä-Liedenpohja J, Louhimo J, Mustonen H, Puolakkainen P: Early gastric cancer: clinical characteristics and results of surgery. Dig Surg; 2009;26(5):378-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early gastric cancer: clinical characteristics and results of surgery.
  • BACKGROUND: Early gastric cancer (EGC) is associated with better prognosis than advanced cancer of the stomach.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19923825.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Sencan O, Buyukcelik A, Yalcin B, Boruban MC, Akbulut H, Demirkazik A, Senler FC, Onur H, Icli F: The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. Eur J Cancer Care (Engl); 2008 Jan;17(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
  • There are few reports on use of symptomatic benefits as an alternative or adjunctive for the assessment of objective response in chemotherapy of the advanced cancer.
  • This study is performed to assess the symptomatic benefits (the clinical benefit response), in addition to the efficacy and toxicity of cisplatin plus infusional 5-fluorouracil (5-FU) combination as second-line therapy in patients with advanced gastric cancer.
  • Fifty-eight advanced gastric cancer patients with previous chemotherapy were enrolled into the study.
  • Cisplatin plus infusional 5-FU combination seems to improve disease-related symptoms (clinical benefit response) of patients with advanced gastric cancer, even in patients without objective response.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181888.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement